guaifenesin has been researched along with Cystic Fibrosis in 548 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Alternative non-ionic osmotic agents such as mannitol may thus be preferable to HS in promoting bronchial mucus clearance (BMC) in patients with cystic fibrosis (CF)." | 9.09 | The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. ( Anderson, SD; Baker, J; Bye, PT; Chan, HK; Daviskas, E; Eberl, S; Robinson, M, 1999) |
| "The therapeutic efficacy of oral N-acetylcysteine (NAC) and ambroxol as compared with the effect of placebos was studied in 36 cystic fibrosis (CF) patients with mild to moderate pulmonary disease." | 9.05 | A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. ( Bender, SW; Hofmann, D; Posselt, HG; Ratjen, F; Stöver, B; Wönne, R, 1985) |
| "The developed SEDDS with amikacin may be a promising tool for the treatment of certain bacterial infections of CF patients." | 7.88 | Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients. ( Bernkop-Schnürch, A; Ellemunter, H; Fontana, S; Griesser, J; Gutierrez, AM; Hetényi, G; Niedermayr, K; Szabó, P, 2018) |
| " Recognizing the thick and tenacious airway mucus seen in the cystic fibrosis (CF) patients as a critical barrier to effective drug delivery, both into the mucus layer itself as well as across that layer to the underlying airway epithelium, we hypothesize that mannitol or NaCl can form inhalable drug carriers, improve drug penetration into the mucus, and ultimately enhance the drug's therapeutic effect." | 7.77 | Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. ( Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y, 2011) |
| "The chronically isoproterenol-treated rat has been proposed as an animal model for cystic fibrosis." | 7.67 | The chronically isoproterenol-treated rat in the study of cystic fibrosis: X-ray microanalysis of the submandibular gland. ( Müller, RM; Roomans, GM, 1984) |
| "Clinical, bronchoscopic, spirographic, scintigraphic, and chemical analyses were done in 24 children with cystic fibrosis to assess the mucolytic effects of acetylcysteine inhalations versus L-arginine hydrochloride aerosols." | 7.65 | Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). ( Dietzsch, HJ; Gottschalk, B; Heyne, K; Leupoid, W; Wunderlich, P, 1975) |
| " Alternative non-ionic osmotic agents such as mannitol may thus be preferable to HS in promoting bronchial mucus clearance (BMC) in patients with cystic fibrosis (CF)." | 5.09 | The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. ( Anderson, SD; Baker, J; Bye, PT; Chan, HK; Daviskas, E; Eberl, S; Robinson, M, 1999) |
| "The therapeutic efficacy of oral N-acetylcysteine (NAC) and ambroxol as compared with the effect of placebos was studied in 36 cystic fibrosis (CF) patients with mild to moderate pulmonary disease." | 5.05 | A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. ( Bender, SW; Hofmann, D; Posselt, HG; Ratjen, F; Stöver, B; Wönne, R, 1985) |
| "We used mass-spectrometry based proteomic analysis of unstimulated and carbachol stimulated newborn wild-type (WT) and cystic fibrosis transmembrane conductance regulator (CFTR) null (CF) piglet airways to study proteins in the airway surface liquid and mucus, to investigate if levels of MUC5AC and MUC5B were affected by carbachol stimulation and whether the proteins clustered according to function." | 4.31 | Proteome of airway surface liquid and mucus in newborn wildtype and cystic fibrosis piglets. ( Bähr, A; Ermund, A; Hansson, GC; Jaudas, F; Klymiuk, N; Rodriguez-Piñeiro, AM, 2023) |
| "The developed SEDDS with amikacin may be a promising tool for the treatment of certain bacterial infections of CF patients." | 3.88 | Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients. ( Bernkop-Schnürch, A; Ellemunter, H; Fontana, S; Griesser, J; Gutierrez, AM; Hetényi, G; Niedermayr, K; Szabó, P, 2018) |
| "Here, the preparation of mucus-penetrating nanoparticles for pulmonary administration of ibuprofen in patients with cystic fibrosis is described." | 3.83 | Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus. ( Cavallaro, G; Craparo, EF; Giammona, G; Porsio, B; Sardo, C, 2016) |
| " Recognizing the thick and tenacious airway mucus seen in the cystic fibrosis (CF) patients as a critical barrier to effective drug delivery, both into the mucus layer itself as well as across that layer to the underlying airway epithelium, we hypothesize that mannitol or NaCl can form inhalable drug carriers, improve drug penetration into the mucus, and ultimately enhance the drug's therapeutic effect." | 3.77 | Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. ( Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y, 2011) |
| "Well-differentiated cultures established from airway epithelia of patients with cystic fibrosis (CF cultures) exhibited goblet cell hyperplasia, increased secretion of mucus, and higher basal levels of interleukin-8 than similarly cultured cells from healthy donors." | 3.72 | Responses of well-differentiated airway epithelial cell cultures from healthy donors and patients with cystic fibrosis to Burkholderia cenocepacia infection. ( Forstner, J; Keshavjee, S; Sajjan, U, 2004) |
| " This problem has been examined by standardizing the macromolecule concentration of sputum from 13 patients suffering from cystic fibrosis, chronic bronchitis or bronchiectasis and adding amikacin to the sputum components." | 3.68 | The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. ( Bataillon, V; Lafitte, JJ; Lhermitte, M; Pommery, J; Roussel, P, 1992) |
| "We have previously shown that a decreased level of phosphatidylglycerol in cystic fibrosis (CF) respiratory mucus is partly responsible for its marked adhesiveness and stickiness, which impair mucus transport, and that distearoyl phosphatidylglycerol (DSPG) was the most efficient form of phosphatidylglycerol in the enhancement of respiratory mucus clearance." | 3.68 | Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus. ( Fuchey, C; Girod de Bentzmann, S; Morançais, JL; Pierrot, D; Puchelle, E; Zahm, JM, 1993) |
| "The chronically isoproterenol-treated rat has been proposed as an animal model for cystic fibrosis." | 3.67 | The chronically isoproterenol-treated rat in the study of cystic fibrosis: X-ray microanalysis of the submandibular gland. ( Müller, RM; Roomans, GM, 1984) |
| "Chronic treatment of rats with reserpine, isoproterenol, or a combination of these two agents has been suggested as a means to produce an experimental animal model for the chronic exocrinopathy cystic fibrosis." | 3.67 | Changes in glycoconjugates in rat submandibular gland after chronic treatment with reserpine and isoproterenol. ( Maltarello, MC; Müller, RM; Roomans, GM; Versura, P, 1988) |
| "Clinical, bronchoscopic, spirographic, scintigraphic, and chemical analyses were done in 24 children with cystic fibrosis to assess the mucolytic effects of acetylcysteine inhalations versus L-arginine hydrochloride aerosols." | 3.65 | Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). ( Dietzsch, HJ; Gottschalk, B; Heyne, K; Leupoid, W; Wunderlich, P, 1975) |
| "Obstructive lung diseases, such as chronic obstructive pulmonary disease, asthma, or non-cystic fibrosis bronchiectasis, share some major pathophysiological features: small airway involvement, dysregulation of adaptive and innate pulmonary immune homeostasis, mucus hyperproduction, and/or hyperconcentration." | 2.82 | Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine! ( Bourdin, A; Charriot, J; Petit, A; Vachier, I; Volpato, M, 2022) |
| "Asthma, chronic obstructive pulmonary disease, and cystic fibrosis are three chronic pulmonary diseases that affect an estimated 420 million individuals across the globe." | 2.58 | Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases. ( Breitzig, MT; Kolliputi, N; Lockey, RF; Saco, TV, 2018) |
| "Cystic fibrosis (CF, mucoviscidosis) is caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), which is a chloride and bicarbonate channel necessary for fluid secretion and extracellular alkalization." | 2.55 | Bicarbonate in cystic fibrosis. ( Hadorn, HB; Kunzelmann, K; Schreiber, R, 2017) |
| "Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have traditionally been viewed as two distinct entities of unrelated origins." | 2.53 | Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. ( Cantin, AM, 2016) |
| "However, there is a risk of gastroesophageal reflux associated with this technique." | 2.52 | Standard (head-down tilt) versus modified (without head-down tilt) postural drainage in infants and young children with cystic fibrosis. ( Chaves, GS; Dias, FA; Ferreira, GM; Freitas, DA; Guerra, RO; Mendonça, KM; Ribeiro, CT, 2015) |
| "Published or unpublished randomised controlled trials (RCTs) or quasi-randomised controlled trials of sodium channel blockers compared to placebo or another sodium channel blocker or the same sodium channel blocker at a different dosing regimen." | 2.50 | Sodium channel blockers for cystic fibrosis. ( Burrows, EF; Noone, PG; Southern, KW, 2014) |
| "Published or unpublished randomised controlled trials (RCTs) or quasi-randomised controlled trials of sodium channel blockers compared to placebo or another sodium channel blocker or the same sodium channel blocker at a different dosing regimen." | 2.48 | Sodium channel blockers for cystic fibrosis. ( Burrows, EF; Noone, PG; Southern, KW, 2012) |
| "Diffuse panbronchiolitis is characterized by chronic inflammation in respiratory bronchioles and sinobronchial infection." | 2.47 | Genetic predisposition to diffuse panbronchiolitis. ( Hijikata, M; Keicho, N, 2011) |
| "Three hereditary disorders, primary ciliary dyskinesia (immotile-cilia syndrome), cystic fibrosis and Young's syndrome, have been shown to be systemically associated with mucociliary transport failure, leading to male infertility and chronic sinopulmonary infections." | 2.38 | [Structure, function and pathophysiology of mucociliary transport system]. ( Manabe, T; Umeki, S, 1992) |
| " A more available CFTR-/- rat model has been developed and characterized to develop CF airway abnormalities, but consistent dosing of pharmacologic agents and longitudinal evaluation remain a challenge." | 1.91 | An ex vivo rat trachea model reveals abnormal airway physiology and a gland secretion defect in cystic fibrosis. ( Barnes, J; Easter, M; Harris, E; Krick, S; Ren, J; Rowe, SM, 2023) |
| "Pretreatment with diminazene aceturate, a small molecule with ability to inhibit acid detection through blockade of the acid-sensing ion channel (ASIC) at the doses provided, did not prevent acid-induced pathologic mucus or transport defects but did mitigate airway obstruction." | 1.56 | Acid exposure disrupts mucus secretion and impairs mucociliary transport in neonatal piglet airways. ( Atanasova, KR; Bravo, L; Collins, EN; Dadural, JS; Eken, E; Guevara, MV; Kuan, SP; Liao, YSJ; Reznikov, LR; Schurmann, V; Sponchiado, M; Vogt, K, 2020) |
| "Cystic fibrosis affects 1/3200 Caucasians." | 1.51 | Influence of frequency and amplitude on the mucus viscoelasticity of the novel mechano-acoustic Frequencer™. ( Boffito, DC; Galli, F; Germon, R; Rigamonti, MG; Schieppati, D; Stucchi, M, 2019) |
| " aeruginosa membrane in a dose-response manner, as demonstrated by flow cytometry." | 1.51 | Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study. ( Aoun, V; Chain, JL; Del'Orto, JC; Derbali, RM; Frei, G; Hildgen, P; Moussa, G; Roullin, VG; Tehrani, SF, 2019) |
| "Dithiothreitol and P3001 were directly compared with NAC in vitro and both exhibited superior reducing activities." | 1.51 | An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. ( Boucher, RC; Delion, MF; Donaldson, SH; Ehre, C; Esther, CR; Fontana, NC; Grubb, BR; Hill, DB; Hothem, LN; Kato, T; Livraghi-Butrico, A; Markovetz, MR; Morrison, CB; Rushton, ZL; Thelin, WR; Villalon, D; Wang, B, 2019) |
| "Depressed MCC in cystic fibrosis is associated with P." | 1.43 | Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung. ( Corcoran, TE; Czachowski, MR; Lacy, RT; Locke, LW; Markovetz, MR; Muthukrishnan, A; Myerburg, MM; Parker, RS; Pilewski, JM; Weber, L; Weiner, DJ, 2016) |
| " Human studies showed that OligoG CF-5/20 is safe for inhalation in CF patients with effective lung deposition and modifies the viscoelasticity of CF-sputum." | 1.43 | A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. ( Dessen, A; Doull, I; Hawkins, K; Hill, KE; Hodges, LA; Lewis, PD; MacGregor, G; Menzies, GE; Myrset, AH; Myrvold, R; Neilly, JB; Onsøyen, E; Powell, LC; Pritchard, MF; Rye, PD; Stevens, HN; Thomas, DW; Walsh, TR; Wright, C, 2016) |
| "Although cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the severity of disease is highly variable indicating the influence of modifier genes." | 1.33 | Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10. ( De Lisle, RC; Norkina, O, 2005) |
| "A total of 248 patients with mucoviscidosis (cystic fibrosis, CF) were assessed by means of nasal endoscopy." | 1.30 | Chronic rhinosinusitis in cystic fibrosis (mucoviscidosis). ( Brihaye, P; Clement, PA; Jorissen, M, 1997) |
| "Cystic fibrosis is associated with severe abnormalities of the capacities of transport, due to the abnormal mucus and inflammatory changes of the epithelium." | 1.29 | [Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis]. ( Puchelle, E; Zahm, JM, 1995) |
| "Guanidine hydrochloride acts as a classical electrolyte in the reversible suppression of charge effects, and not as a denaturing or dissociation agent." | 1.27 | Polyelectrolyte behaviour in mucus glycoproteins. ( Creeth, JM; Harding, SE, 1983) |
| "The hallmark of cystic fibrosis is progressive bronchopulmonary damage associated with chronic infection with Pseudomonas aeruginosa, leading to respiratory failure and, ultimately, death." | 1.27 | Immunologic aspects of surface infections in the lung. ( Ogra, PL; Piedra, P, 1986) |
| "Cystic fibrosis is characterized by an abnormally high electrolyte concentration in exocrine secretions." | 1.27 | Tear mucus crystallization in children with cystic fibrosis. ( Baldi, F; Calabria, G; Rolando, M, 1988) |
| "Focal biliary cirrhosis is an uncommon finding in infants with cystic fibrosis, but it is present in more than a fifth of surviving children and adolescents." | 1.25 | Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. ( Esterly, JR; Oppenheimer, EH, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 170 (31.02) | 18.7374 |
| 1990's | 66 (12.04) | 18.2507 |
| 2000's | 96 (17.52) | 29.6817 |
| 2010's | 156 (28.47) | 24.3611 |
| 2020's | 60 (10.95) | 2.80 |
| Authors | Studies |
|---|---|
| Dhar, R | 1 |
| Moore, JE | 1 |
| Millar, BC | 1 |
| Ghanem, R | 1 |
| Roquefort, P | 1 |
| Ramel, S | 1 |
| Laurent, V | 1 |
| Haute, T | 1 |
| Le Gall, T | 1 |
| Aubry, T | 1 |
| Montier, T | 1 |
| Butnarasu, C | 1 |
| Caron, G | 1 |
| Pacheco, DP | 1 |
| Petrini, P | 1 |
| Visentin, S | 1 |
| Brody, AS | 2 |
| Huang, R | 1 |
| Zhang, B | 1 |
| Long, FR | 2 |
| Powers, SW | 1 |
| Hill, DB | 12 |
| Button, B | 15 |
| Rubinstein, M | 4 |
| Boucher, RC | 33 |
| Yu, W | 1 |
| Moninger, TO | 5 |
| Thurman, AL | 1 |
| Xie, Y | 3 |
| Jain, A | 1 |
| Zarei, K | 1 |
| Powers, LS | 1 |
| Pezzulo, AA | 3 |
| Stoltz, DA | 8 |
| Welsh, MJ | 8 |
| Conte, G | 2 |
| Costabile, G | 1 |
| Baldassi, D | 1 |
| Rondelli, V | 1 |
| Bassi, R | 1 |
| Colombo, D | 1 |
| Linardos, G | 1 |
| Fiscarelli, EV | 1 |
| Sorrentino, R | 1 |
| Miro, A | 1 |
| Quaglia, F | 1 |
| Brocca, P | 1 |
| d'Angelo, I | 2 |
| Merkel, OM | 1 |
| Ungaro, F | 2 |
| Charriot, J | 1 |
| Volpato, M | 1 |
| Petit, A | 1 |
| Vachier, I | 1 |
| Bourdin, A | 1 |
| Abrami, M | 1 |
| Maschio, M | 1 |
| Conese, M | 3 |
| Confalonieri, M | 1 |
| Salton, F | 1 |
| Gerin, F | 1 |
| Dapas, B | 1 |
| Farra, R | 1 |
| Adrover, A | 1 |
| Milcovich, G | 1 |
| Fornasier, C | 1 |
| Biasin, A | 1 |
| Grassi, M | 1 |
| Grassi, G | 1 |
| Zorzo, C | 1 |
| Girón, RM | 1 |
| Hernández, S | 1 |
| Gómez-Punter, RM | 1 |
| Caballero, P | 1 |
| Pino-Argumedo, MI | 1 |
| Fischer, AJ | 3 |
| Hilkin, BM | 1 |
| Gansemer, ND | 1 |
| Allen, PD | 1 |
| Hoffman, EA | 2 |
| Abou Alaiwa, MH | 2 |
| Kato, T | 3 |
| Radicioni, G | 2 |
| Papanikolas, MJ | 2 |
| Stoychev, GV | 1 |
| Markovetz, MR | 10 |
| Aoki, K | 1 |
| Porterfield, M | 1 |
| Okuda, K | 3 |
| Barbosa Cardenas, SM | 1 |
| Gilmore, RC | 3 |
| Morrison, CB | 6 |
| Ehre, C | 9 |
| Burns, KA | 1 |
| White, KK | 1 |
| Brennan, TA | 1 |
| Goodell, HP | 2 |
| Thacker, H | 1 |
| Loznev, HT | 1 |
| Forsberg, LJ | 1 |
| Nagase, T | 1 |
| Randell, SH | 6 |
| Tiemeyer, M | 2 |
| Kesimer, M | 6 |
| O'Neal, WK | 4 |
| Ballard, ST | 5 |
| Freeman, R | 2 |
| Einarsson, GG | 1 |
| Vanaudenaerde, BM | 1 |
| Spence, CD | 1 |
| Lee, AJ | 1 |
| Boon, M | 1 |
| Verleden, GM | 1 |
| Elborn, JS | 5 |
| Dupont, LJ | 1 |
| Van Raemdonck, D | 1 |
| Gilpin, DF | 1 |
| Vos, R | 1 |
| Verleden, SE | 1 |
| Tunney, MM | 2 |
| Garbarine, IC | 3 |
| Kissner, WJ | 3 |
| Seim, I | 2 |
| Forest, MG | 4 |
| Ceppe, A | 3 |
| Ghio, A | 1 |
| Alexis, NE | 2 |
| Stick, SM | 3 |
| Esther, CR | 3 |
| Muhlebach, MS | 3 |
| Batson, BD | 2 |
| Zorn, BT | 1 |
| Livengood, SS | 1 |
| Kumagai, T | 1 |
| Dang, H | 2 |
| Clapp, PW | 1 |
| Tunney, M | 1 |
| McElvaney, NG | 4 |
| Wolfgang, MC | 2 |
| Ma, J | 4 |
| Trimble, A | 1 |
| Zeman, K | 1 |
| Wu, J | 1 |
| Bennett, W | 1 |
| Donaldson, S | 1 |
| Golec, A | 1 |
| Pranke, I | 1 |
| Scudieri, P | 2 |
| Hayes, K | 1 |
| Dreano, E | 1 |
| Dunlevy, F | 1 |
| Hatton, A | 1 |
| Downey, DG | 1 |
| Galietta, L | 1 |
| Sermet, I | 1 |
| Figueira, MF | 1 |
| Ribeiro, CMP | 2 |
| Poncin, W | 1 |
| Lebret, M | 1 |
| Maerckx, G | 1 |
| Rouillard, KR | 2 |
| Hansson, GC | 11 |
| Thornton, DJ | 4 |
| Ostedgaard, LS | 4 |
| Shaffer, KM | 2 |
| Raywood, E | 1 |
| Shannon, H | 1 |
| Filipow, N | 1 |
| Tanriver, G | 1 |
| Stanojevic, S | 1 |
| Kapoor, K | 1 |
| Douglas, H | 1 |
| O'Connor, R | 1 |
| Murray, N | 1 |
| Black, B | 1 |
| Main, E | 1 |
| Kohout, VR | 1 |
| Wardzala, CL | 1 |
| Kramer, JR | 1 |
| Wilson, LM | 1 |
| Saldanha, IJ | 1 |
| Robinson, KA | 1 |
| Pangeni, R | 1 |
| Meng, T | 2 |
| Poudel, S | 1 |
| Sharma, D | 1 |
| Hutsell, H | 1 |
| Rubin, BK | 17 |
| Longest, W | 1 |
| Hindle, M | 2 |
| Xu, Q | 2 |
| Rodriguez-Piñeiro, AM | 2 |
| Jaudas, F | 1 |
| Klymiuk, N | 3 |
| Bähr, A | 3 |
| Ermund, A | 8 |
| Roe, AH | 1 |
| Koelper, N | 1 |
| McAllister, A | 1 |
| Barnhart, KT | 1 |
| Schreiber, CA | 1 |
| Hadjiliadis, D | 1 |
| Boboltz, A | 1 |
| Yang, S | 1 |
| Duncan, GA | 3 |
| Watson, K | 1 |
| Koenig, E | 1 |
| Bannister, A | 1 |
| Mayne, V | 1 |
| Jacques, A | 1 |
| Sawyer, A | 1 |
| Wood, J | 1 |
| Harris, E | 1 |
| Easter, M | 1 |
| Ren, J | 1 |
| Krick, S | 1 |
| Barnes, J | 1 |
| Rowe, SM | 8 |
| Leung, HM | 2 |
| Birket, SE | 7 |
| Hyun, C | 1 |
| Ford, TN | 1 |
| Cui, D | 1 |
| Solomon, GM | 1 |
| Shei, RJ | 1 |
| Adewale, AT | 1 |
| Lenzie, AR | 1 |
| Fernandez-Petty, CM | 3 |
| Zheng, H | 1 |
| Palermo, JH | 1 |
| Cho, DY | 1 |
| Woodworth, BA | 1 |
| Yonker, LM | 1 |
| Hurley, BP | 1 |
| Tearney, GJ | 5 |
| Cabrita, I | 3 |
| Benedetto, R | 3 |
| Schreiber, R | 4 |
| Kunzelmann, K | 4 |
| Chen, G | 1 |
| Sun, L | 1 |
| Martino, MB | 1 |
| Abzhanova, A | 1 |
| Lin, JM | 1 |
| O'Neal, YK | 1 |
| Volmer, AS | 1 |
| Deng, Y | 1 |
| Livraghi-Butrico, A | 2 |
| Ribeiro, CM | 2 |
| Lababidi, N | 1 |
| Ofosu Kissi, E | 1 |
| Elgaher, WAM | 1 |
| Sigal, V | 1 |
| Haupenthal, J | 1 |
| Schwarz, BC | 2 |
| Hirsch, AKH | 1 |
| Rades, T | 1 |
| Schneider, M | 4 |
| Garić, D | 1 |
| De Sanctis, JB | 1 |
| Dumut, DC | 1 |
| Shah, J | 1 |
| Peña, MJ | 1 |
| Youssef, M | 1 |
| Petrof, BJ | 1 |
| Kopriva, F | 1 |
| Hanrahan, JW | 3 |
| Hajduch, M | 1 |
| Radzioch, D | 1 |
| Balázs, A | 1 |
| Mall, MA | 7 |
| Simões, FB | 1 |
| Quaresma, MC | 1 |
| Clarke, LA | 1 |
| Silva, IA | 1 |
| Pankonien, I | 1 |
| Railean, V | 1 |
| Kmit, A | 1 |
| Amaral, MD | 1 |
| Turcios, NL | 1 |
| McIlwaine, M | 2 |
| Nevitt, SJ | 1 |
| Danahay, HL | 1 |
| Lilley, S | 1 |
| Fox, R | 1 |
| Charlton, H | 1 |
| Sabater, J | 1 |
| McCarthy, C | 1 |
| Collingwood, SP | 1 |
| Gosling, M | 1 |
| Robinson, TE | 1 |
| Goris, ML | 1 |
| Moss, RB | 1 |
| Tian, L | 1 |
| Kan, P | 1 |
| Yilma, M | 1 |
| McCoy, KS | 1 |
| Newman, B | 1 |
| de Jong, PA | 1 |
| Behrje, R | 1 |
| Yates, DP | 1 |
| Cornfield, DN | 1 |
| Gianotti, A | 2 |
| Capurro, V | 2 |
| Delpiano, L | 1 |
| Mielczarek, M | 1 |
| García-Valverde, M | 1 |
| Carreira-Barral, I | 1 |
| Ludovico, A | 1 |
| Fiore, M | 1 |
| Baroni, D | 1 |
| Moran, O | 2 |
| Quesada, R | 1 |
| Caci, E | 1 |
| Turkovic, L | 2 |
| Caudri, D | 2 |
| Rosenow, T | 1 |
| Breuer, O | 1 |
| Murray, C | 1 |
| Tiddens, HAWM | 1 |
| Ramanauskas, F | 1 |
| Ranganathan, SC | 1 |
| Hall, GL | 1 |
| Liao, YSJ | 1 |
| Kuan, SP | 1 |
| Guevara, MV | 1 |
| Collins, EN | 1 |
| Atanasova, KR | 2 |
| Dadural, JS | 1 |
| Vogt, K | 1 |
| Schurmann, V | 1 |
| Bravo, L | 1 |
| Eken, E | 1 |
| Sponchiado, M | 1 |
| Reznikov, LR | 2 |
| Schoenfisch, MH | 1 |
| Leal, J | 3 |
| Peng, X | 1 |
| Liu, X | 2 |
| Arasappan, D | 1 |
| Wylie, DC | 1 |
| Schwartz, SH | 1 |
| Fullmer, JJ | 1 |
| McWilliams, BC | 1 |
| Smyth, HDC | 3 |
| Ghosh, D | 2 |
| Leemans, G | 1 |
| Belmans, D | 1 |
| Van Holsbeke, C | 1 |
| Becker, B | 1 |
| Vissers, D | 1 |
| Ides, K | 1 |
| Verhulst, S | 1 |
| Van Hoorenbeeck, K | 1 |
| Morrison, L | 4 |
| Milroy, S | 1 |
| Davis, JM | 2 |
| Henderson, AG | 3 |
| Oden, AM | 2 |
| Tang, L | 1 |
| Wen, H | 1 |
| Hong, J | 1 |
| Fu, L | 1 |
| Chambers, A | 1 |
| Fields, A | 1 |
| Zhao, G | 1 |
| Sorscher, EJ | 4 |
| Chai, G | 1 |
| Hassan, A | 1 |
| Lou, L | 1 |
| Simmers, R | 1 |
| Zhou, L | 1 |
| Zhou, QT | 1 |
| Longest, PW | 1 |
| Hisert, KB | 1 |
| Lu, L | 2 |
| Tang, XX | 2 |
| Huang, TJ | 1 |
| Bengtson, CD | 1 |
| Kim, MD | 1 |
| Anabtawi, A | 1 |
| He, J | 1 |
| Dennis, JS | 1 |
| Miller, S | 1 |
| Yoshida, M | 1 |
| Baumlin, N | 1 |
| Salathe, M | 1 |
| Wheelock, CE | 1 |
| Strandvik, B | 1 |
| Widdicombe, JH | 4 |
| Wanitchakool, P | 1 |
| Lerias, J | 1 |
| Centeio, R | 2 |
| Ousingsawat, J | 2 |
| Tschernig, T | 1 |
| Sears, PR | 1 |
| Bustamante-Marin, XM | 1 |
| Gong, H | 1 |
| Superfine, R | 2 |
| Ostrowski, LE | 2 |
| Comegna, M | 1 |
| Falanga, AP | 1 |
| Marzano, M | 1 |
| Cernera, G | 1 |
| Di Lullo, AM | 1 |
| Amato, F | 1 |
| Borbone, N | 1 |
| D'Errico, S | 1 |
| Oliviero, G | 1 |
| Castaldo, G | 1 |
| Delfino, D | 1 |
| Mori, G | 1 |
| Rivetti, C | 1 |
| Grigoletto, A | 1 |
| Bizzotto, G | 1 |
| Cavozzi, C | 1 |
| Malatesta, M | 1 |
| Cavazzini, D | 1 |
| Pasut, G | 1 |
| Percudani, R | 1 |
| Brown, R | 1 |
| Small, DM | 2 |
| Doherty, DF | 2 |
| Holsinger, L | 2 |
| Booth, R | 2 |
| Williams, R | 2 |
| Ingram, RJ | 1 |
| Taggart, CC | 2 |
| Weldon, S | 2 |
| Giorgetti, M | 1 |
| Hemmerling, M | 1 |
| Jinton, L | 1 |
| Tarran, R | 9 |
| Malmgren, A | 1 |
| Åstrand, A | 2 |
| Araba, KC | 1 |
| Wykoff, JA | 1 |
| Quinney, NL | 1 |
| Hao, S | 1 |
| Delion, MF | 3 |
| Flen, AL | 1 |
| Morton, LC | 1 |
| Liao, J | 1 |
| Drumm, ML | 3 |
| Gentzsch, M | 1 |
| Choudhary, I | 1 |
| Vo, T | 1 |
| Paudel, K | 1 |
| Yadav, R | 1 |
| Mao, Y | 1 |
| Patial, S | 2 |
| Saini, Y | 2 |
| Talbi, K | 1 |
| Doušová, T | 1 |
| Verbeken, EK | 1 |
| De Boeck, K | 1 |
| Cohen, I | 1 |
| Innes, S | 1 |
| Günday Türeli, N | 1 |
| Torge, A | 2 |
| Juntke, J | 1 |
| Schneider-Daum, N | 1 |
| Türeli, AE | 1 |
| Lehr, CM | 2 |
| Wagner, S | 1 |
| Chaves, PS | 1 |
| Oliveira, EG | 1 |
| Guterres, SS | 1 |
| Pohlmann, AR | 1 |
| Titz, A | 1 |
| Beck, RCR | 1 |
| Comstock, WJ | 1 |
| Huh, E | 1 |
| Weekes, R | 1 |
| Watson, C | 1 |
| Xu, T | 1 |
| Dorrestein, PC | 1 |
| Quinn, RA | 1 |
| Dournes, G | 2 |
| Berger, P | 2 |
| Refait, J | 2 |
| Macey, J | 2 |
| Bui, S | 2 |
| Delhaes, L | 2 |
| Montaudon, M | 1 |
| Corneloup, O | 1 |
| Chateil, JF | 1 |
| Marthan, R | 1 |
| Fayon, M | 2 |
| Laurent, F | 2 |
| Carraro, G | 1 |
| Stripp, BR | 1 |
| Lewis, BW | 1 |
| Sultana, R | 1 |
| Sharma, R | 1 |
| Noël, A | 1 |
| Langohr, I | 1 |
| Penn, AL | 1 |
| Occelli, A | 1 |
| Soize, S | 1 |
| Ranc, C | 1 |
| Giovannini-Chami, L | 1 |
| Bailly, C | 1 |
| Leloutre, B | 1 |
| Boyer, C | 1 |
| Baque-Juston, M | 1 |
| Hadorn, HB | 1 |
| Poetker, DM | 1 |
| McCormack, P | 1 |
| Burnham, P | 1 |
| Southern, KW | 3 |
| Saco, TV | 1 |
| Breitzig, MT | 1 |
| Lockey, RF | 1 |
| Kolliputi, N | 1 |
| Voynow, JA | 3 |
| Porsio, B | 4 |
| Craparo, EF | 4 |
| Mauro, N | 1 |
| Giammona, G | 4 |
| Cavallaro, G | 5 |
| Nafee, N | 1 |
| Forier, K | 1 |
| Braeckmans, K | 1 |
| Fernandez, CM | 2 |
| Tuggle, KL | 1 |
| Chu, KK | 3 |
| Fanucchi, MV | 1 |
| Shen, Y | 1 |
| Huang, S | 1 |
| Kang, J | 1 |
| Lin, J | 1 |
| Lai, K | 1 |
| Sun, Y | 1 |
| Xiao, W | 1 |
| Yang, L | 1 |
| Yao, W | 1 |
| Cai, S | 1 |
| Huang, K | 1 |
| Wen, F | 1 |
| Wan, F | 1 |
| Nylander, T | 1 |
| Klodzinska, SN | 1 |
| Foged, C | 1 |
| Yang, M | 1 |
| Baldursdottir, SG | 1 |
| M Nielsen, H | 1 |
| Hetényi, G | 2 |
| Griesser, J | 2 |
| Fontana, S | 1 |
| Gutierrez, AM | 1 |
| Ellemunter, H | 2 |
| Niedermayr, K | 2 |
| Szabó, P | 1 |
| Bernkop-Schnürch, A | 2 |
| Bahamondez-Canas, TF | 1 |
| Zhang, H | 1 |
| Tewes, F | 1 |
| Lu, HD | 1 |
| Pearson, E | 1 |
| Ristroph, KD | 1 |
| Ensign, LM | 1 |
| Suk, JS | 4 |
| Hanes, J | 7 |
| Prud'homme, RK | 1 |
| Rimessi, A | 1 |
| Bezzerri, V | 1 |
| Salvatori, F | 1 |
| Tamanini, A | 1 |
| Nigro, F | 1 |
| Dechecchi, MC | 1 |
| Santangelo, A | 1 |
| Prandini, P | 1 |
| Munari, S | 1 |
| Provezza, L | 1 |
| Garreau de Loubresse, N | 1 |
| Muller, J | 1 |
| Lippi, G | 1 |
| Gambari, R | 1 |
| Pinton, P | 1 |
| Cabrini, G | 1 |
| Delgado Pecellín, I | 1 |
| Moreno Ortega, M | 1 |
| Carrasco Hernández, L | 1 |
| Marín Barrera, L | 1 |
| Muñoz Zara, P | 1 |
| Moreno Valera, MJ | 1 |
| Quintana Gallego, ME | 1 |
| Meiss, LN | 4 |
| Dolan, B | 1 |
| Ernst, J | 1 |
| Klinger-Strobel, M | 1 |
| Arnold, K | 1 |
| Thamm, J | 1 |
| Hartung, A | 1 |
| Pletz, MW | 1 |
| Makarewicz, O | 1 |
| Fischer, D | 1 |
| Zhao, C | 1 |
| Crosby, J | 1 |
| Lv, T | 1 |
| Bai, D | 1 |
| Monia, BP | 1 |
| Guo, S | 1 |
| Birket, S | 1 |
| Fernández-Blanco, JA | 1 |
| Fakih, D | 1 |
| Arike, L | 1 |
| Martínez-Abad, B | 1 |
| Skansebo, E | 1 |
| Jackson, S | 1 |
| Root, J | 1 |
| Singh, D | 1 |
| McCrae, C | 1 |
| Evans, CM | 2 |
| Rushton, ZL | 1 |
| Wang, B | 1 |
| Hothem, LN | 1 |
| Fontana, NC | 2 |
| Villalon, D | 2 |
| Thelin, WR | 2 |
| Grubb, BR | 7 |
| Donaldson, SH | 6 |
| Dong, T | 1 |
| Taylor, A | 1 |
| Siegrist, E | 1 |
| Gao, F | 1 |
| Sala, V | 1 |
| Murabito, A | 1 |
| Ghigo, A | 1 |
| Long, RF | 1 |
| Atieh, E | 2 |
| Christy, M | 1 |
| Habibpour, M | 1 |
| Plyler, ZE | 1 |
| Schultz, BD | 2 |
| Hong, JS | 1 |
| Petty, CF | 1 |
| Crowley, MR | 1 |
| Crossman, DK | 1 |
| Schoeb, TR | 1 |
| Chen, YC | 1 |
| Shenoy, S | 1 |
| Lackey, E | 1 |
| Shenkute, NT | 1 |
| Cai, LH | 1 |
| Dennis, RG | 1 |
| Ostedgaard, L | 1 |
| Cristallini, C | 1 |
| Barbani, N | 1 |
| Ventrelli, L | 1 |
| Summa, C | 1 |
| Filippi, S | 1 |
| Capelôa, T | 1 |
| Vitale, E | 1 |
| Albera, C | 1 |
| Messore, B | 1 |
| Giachino, C | 1 |
| Castellani, S | 2 |
| Di Gioia, S | 2 |
| di Toma, L | 1 |
| Federer, C | 1 |
| Steinbring, C | 1 |
| Brown, RR | 1 |
| Abladey, A | 1 |
| Zhou-Suckow, Z | 2 |
| Delaney, RJ | 1 |
| Kerrigan, L | 1 |
| Dougan, CM | 1 |
| Borensztajn, KS | 1 |
| Scott, CJ | 1 |
| López-Campos, G | 1 |
| Chen, H | 1 |
| Mansfield, EDH | 1 |
| Woods, A | 1 |
| Khutoryanskiy, VV | 1 |
| Forbes, B | 1 |
| Jones, SA | 1 |
| Derbali, RM | 1 |
| Aoun, V | 1 |
| Moussa, G | 1 |
| Frei, G | 1 |
| Tehrani, SF | 1 |
| Del'Orto, JC | 1 |
| Hildgen, P | 1 |
| Roullin, VG | 1 |
| Chain, JL | 1 |
| Sardo, C | 2 |
| Di Domenico, EG | 1 |
| De Rocco, D | 1 |
| Santucci, R | 1 |
| Ascenzioni, F | 1 |
| Ramsey, KA | 1 |
| Zorn, B | 1 |
| Sabater, JR | 2 |
| Ranganathan, S | 1 |
| Hughes, GW | 1 |
| Bowers, HL | 1 |
| Watson, JD | 1 |
| Rosen, BH | 1 |
| Townsend, SM | 1 |
| Santos, C | 1 |
| Ridley, CE | 1 |
| Li, Y | 2 |
| Mazur, M | 1 |
| Garcia, BA | 1 |
| Evans, TIA | 1 |
| Libby, EF | 1 |
| Hathorne, H | 1 |
| Clancy, JP | 1 |
| Engelhardt, JF | 3 |
| Swords, WE | 1 |
| Wiesmann, WP | 1 |
| Baker, SM | 1 |
| Schieppati, D | 1 |
| Germon, R | 1 |
| Galli, F | 1 |
| Rigamonti, MG | 1 |
| Stucchi, M | 1 |
| Boffito, DC | 1 |
| Stigliani, M | 2 |
| Aquino, RP | 2 |
| Del Gaudio, P | 1 |
| Mencherini, T | 1 |
| Sansone, F | 1 |
| Russo, P | 2 |
| Button, BM | 1 |
| Osman, R | 1 |
| Al Jamal, KT | 1 |
| Kan, PL | 1 |
| Awad, G | 1 |
| Mortada, N | 1 |
| El-Shamy, AE | 1 |
| Alpar, O | 1 |
| Yin, Y | 1 |
| Withers, TR | 1 |
| Wang, X | 2 |
| Yu, HD | 1 |
| Warnock, L | 2 |
| Gates, A | 2 |
| van der Schans, CP | 2 |
| Garland, AL | 1 |
| Walton, WG | 1 |
| Coakley, RD | 1 |
| Tan, CD | 1 |
| Hobbs, CA | 1 |
| Tripathy, A | 1 |
| Clunes, LA | 1 |
| Bencharit, S | 1 |
| Stutts, MJ | 1 |
| Betts, L | 1 |
| Redinbo, MR | 1 |
| Laube, BL | 1 |
| Sharpless, G | 1 |
| Benson, J | 1 |
| Carson, KA | 1 |
| Mogayzel, PJ | 1 |
| Tomaiuolo, G | 1 |
| Rusciano, G | 1 |
| Caserta, S | 1 |
| Carciati, A | 1 |
| Carnovale, V | 1 |
| Abete, P | 1 |
| Sasso, A | 1 |
| Guido, S | 1 |
| Kim, AJ | 1 |
| Trehan, K | 1 |
| Schneider, CS | 1 |
| Cebotaru, L | 1 |
| Woodward, OM | 1 |
| Boylan, NJ | 1 |
| Boyle, MP | 3 |
| Lai, SK | 1 |
| Guggino, WB | 2 |
| Vasquez, PA | 1 |
| Mellnik, J | 1 |
| McKinley, SA | 1 |
| Vose, A | 1 |
| Mu, F | 1 |
| Sun, X | 1 |
| Olivier, AK | 1 |
| Yi, Y | 1 |
| Pope, CE | 1 |
| Hayden, HS | 1 |
| Liang, B | 1 |
| Sui, H | 1 |
| Zhou, W | 1 |
| Hager, KR | 1 |
| Zhang, Y | 1 |
| Yan, Z | 1 |
| Fisher, JT | 1 |
| Keiser, NW | 1 |
| Song, Y | 2 |
| Tyler, SR | 1 |
| Goeken, JA | 1 |
| Kinyon, JM | 1 |
| Radey, MC | 1 |
| Fligg, D | 1 |
| Xie, W | 1 |
| Lynch, TJ | 1 |
| Kaminsky, PM | 1 |
| Brittnacher, MJ | 1 |
| Miller, SI | 1 |
| Parekh, K | 1 |
| Meyerholz, DK | 3 |
| Hoffman, LR | 1 |
| Frana, T | 1 |
| Stewart, ZA | 1 |
| Gehrig, S | 1 |
| Duerr, J | 2 |
| Weitnauer, M | 1 |
| Wagner, CJ | 2 |
| Graeber, SY | 1 |
| Schatterny, J | 2 |
| Hirtz, S | 3 |
| Belaaouaj, A | 1 |
| Dalpke, AH | 1 |
| Schultz, C | 2 |
| Burrows, EF | 2 |
| Noone, PG | 2 |
| Jeong, JH | 1 |
| Joo, NS | 6 |
| Hwang, PH | 1 |
| Wine, JJ | 7 |
| Trojanek, JB | 1 |
| Cobos-Correa, A | 1 |
| Diemer, S | 1 |
| Kormann, M | 1 |
| Schubert, SC | 1 |
| Agrawal, R | 1 |
| Sommerburg, O | 1 |
| Hartl, D | 1 |
| Agnew, J | 2 |
| Hoegger, MJ | 2 |
| McMenimen, JD | 2 |
| Tucker, AJ | 1 |
| Awadalla, MA | 1 |
| Michalski, AS | 1 |
| Zabner, J | 2 |
| Schwab, U | 2 |
| Abdullah, LH | 1 |
| Perlmutt, OS | 1 |
| Albert, D | 1 |
| Davis, CW | 4 |
| Arnold, RR | 1 |
| Yankaskas, JR | 3 |
| Gilligan, P | 1 |
| Neubauer, H | 1 |
| Nair, C | 1 |
| Shoemark, A | 1 |
| Chan, M | 1 |
| Ollosson, S | 1 |
| Dixon, M | 1 |
| Hogg, C | 1 |
| Alton, EW | 4 |
| Davies, JC | 1 |
| Williams, HD | 1 |
| Scholte, BJ | 1 |
| Yuan, S | 1 |
| Hollinger, M | 1 |
| Lachowicz-Scroggins, ME | 1 |
| Kerr, SC | 1 |
| Dunican, EM | 1 |
| Daniel, BM | 1 |
| Ghosh, S | 1 |
| Erzurum, SC | 1 |
| Willard, B | 1 |
| Hazen, SL | 1 |
| Huang, X | 1 |
| Carrington, SD | 1 |
| Oscarson, S | 1 |
| Fahy, JV | 2 |
| Kurbatova, P | 1 |
| Bessonov, N | 1 |
| Volpert, V | 1 |
| Tiddens, HA | 2 |
| Cornu, C | 1 |
| Nony, P | 1 |
| Hardy, CL | 1 |
| King, SJ | 1 |
| Mifsud, NA | 1 |
| Hedger, MP | 1 |
| Phillips, DJ | 1 |
| Mackay, F | 1 |
| de Kretser, DM | 1 |
| Wilson, JW | 1 |
| Rolland, JM | 1 |
| O'Hehir, RE | 1 |
| Freitas, DA | 1 |
| Dias, FA | 1 |
| Chaves, GS | 1 |
| Ferreira, GM | 1 |
| Ribeiro, CT | 1 |
| Guerra, RO | 1 |
| Mendonça, KM | 1 |
| Tildy, BE | 1 |
| Rogers, DF | 3 |
| Dwan, K | 1 |
| Mastorakos, P | 1 |
| da Silva, AL | 1 |
| Chisholm, J | 1 |
| Song, E | 1 |
| Choi, WK | 1 |
| Morales, MM | 1 |
| Gustafsson, JK | 2 |
| Trapani, A | 1 |
| Carbone, A | 1 |
| Belgiovine, G | 1 |
| Puglisi, G | 1 |
| Trapani, G | 1 |
| Galietta, LJ | 1 |
| Zegarra-Moran, O | 1 |
| Karp, PH | 2 |
| Choudhury, B | 1 |
| Varki, A | 1 |
| Pritchard, MF | 1 |
| Powell, LC | 1 |
| Menzies, GE | 1 |
| Lewis, PD | 1 |
| Hawkins, K | 1 |
| Wright, C | 1 |
| Doull, I | 1 |
| Walsh, TR | 1 |
| Onsøyen, E | 3 |
| Dessen, A | 3 |
| Myrvold, R | 1 |
| Rye, PD | 3 |
| Myrset, AH | 3 |
| Stevens, HN | 1 |
| Hodges, LA | 1 |
| MacGregor, G | 1 |
| Neilly, JB | 1 |
| Hill, KE | 1 |
| Thomas, DW | 1 |
| Safe, M | 1 |
| Gifford, AJ | 1 |
| Jaffe, A | 1 |
| Ooi, CY | 1 |
| Locke, LW | 1 |
| Myerburg, MM | 1 |
| Weiner, DJ | 1 |
| Parker, RS | 1 |
| Muthukrishnan, A | 1 |
| Weber, L | 1 |
| Czachowski, MR | 1 |
| Lacy, RT | 1 |
| Pilewski, JM | 1 |
| Corcoran, TE | 1 |
| Cantin, AM | 1 |
| Anderson, WH | 1 |
| Bennett, WD | 2 |
| Chatelin, R | 2 |
| Poncet, P | 2 |
| Vitko, M | 1 |
| Valerio, DM | 1 |
| Hodges, CA | 1 |
| Scales, BS | 1 |
| Dickson, RP | 1 |
| Huffnagle, GB | 1 |
| Bayes, HK | 1 |
| Ritchie, ND | 1 |
| Ward, C | 1 |
| Corris, PA | 1 |
| Brodlie, M | 1 |
| Evans, TJ | 1 |
| Tridello, G | 1 |
| Menin, L | 1 |
| Pintani, E | 1 |
| Bergamini, G | 1 |
| Assael, BM | 1 |
| Melotti, P | 1 |
| Mojahed, D | 1 |
| Liu, L | 1 |
| Wilsterman, EJ | 1 |
| Diephuis, B | 1 |
| Bowers, H | 1 |
| Martin Solomon, G | 1 |
| Schuster, BS | 1 |
| Jung, J | 1 |
| Joseph, A | 1 |
| Thaxton, AL | 1 |
| West, NE | 1 |
| Kupferschmidt, K | 1 |
| Schillaci, D | 1 |
| Cusimano, MG | 1 |
| Spigolon, D | 1 |
| Biswas, K | 1 |
| Chang, A | 1 |
| Hoggard, M | 1 |
| Radcliff, FJ | 1 |
| Jiang, Y | 1 |
| Taylor, MW | 1 |
| Darveau, R | 1 |
| Douglas, RG | 1 |
| Alrahman, MA | 1 |
| Yoon, SS | 4 |
| Ernst, M | 1 |
| John, T | 1 |
| Guenther, M | 1 |
| Wagner, C | 1 |
| Schaefer, UF | 1 |
| Anne-Archard, D | 1 |
| Murris-Espin, M | 1 |
| Thiriet, M | 1 |
| Recktenwald, CV | 1 |
| Skjåk-Braek, G | 1 |
| Quinton, PM | 6 |
| Koo, JS | 1 |
| Griesenbach, U | 2 |
| Taylor-Cousar, JL | 1 |
| Zariwala, MA | 1 |
| Burch, LH | 1 |
| Pace, RG | 1 |
| Calloway, H | 1 |
| Fan, H | 1 |
| Weston, BW | 1 |
| Wright, FA | 1 |
| Knowles, MR | 1 |
| Choi, JY | 3 |
| Khansaheb, M | 2 |
| Krouse, ME | 4 |
| Robbins, RC | 2 |
| Weill, D | 1 |
| Frerichs, C | 1 |
| Smyth, A | 1 |
| Zhang, L | 2 |
| Gabriel, SE | 1 |
| Burkett, S | 1 |
| Yan, Y | 1 |
| Skiadopoulos, MH | 1 |
| Dang, YL | 1 |
| Vogel, LN | 1 |
| McKay, T | 1 |
| Mengos, A | 1 |
| Collins, PL | 2 |
| Pickles, RJ | 2 |
| Mateos-Corral, D | 1 |
| Cutz, E | 1 |
| Solomon, M | 1 |
| Ratjen, F | 3 |
| Garcia, MA | 1 |
| Yang, N | 1 |
| Pisi, G | 2 |
| Chetta, A | 1 |
| Daviskas, E | 3 |
| Anderson, SD | 2 |
| Jaques, A | 1 |
| Charlton, B | 1 |
| Rosenfeld, M | 1 |
| Paré, PD | 1 |
| Gulbins, E | 1 |
| Schmidt, HJ | 1 |
| Bhandari, V | 1 |
| Bhandari, A | 1 |
| Davies, J | 1 |
| Marshall, BC | 1 |
| Praud, JP | 1 |
| Zar, HJ | 1 |
| Ramachandran, S | 1 |
| Rogan, MP | 1 |
| Davis, GJ | 1 |
| Hanfland, RA | 1 |
| Wohlford-Lenane, C | 1 |
| Dohrn, CL | 1 |
| Bartlett, JA | 1 |
| Nelson, GA | 1 |
| Chang, EH | 1 |
| Taft, PJ | 1 |
| Ludwig, PS | 1 |
| Estin, M | 1 |
| Hornick, EE | 1 |
| Launspach, JL | 1 |
| Samuel, M | 1 |
| Rokhlina, T | 1 |
| Uc, A | 1 |
| Starner, TD | 1 |
| Horswill, AR | 1 |
| Brogden, KA | 1 |
| Prather, RS | 1 |
| Richter, SS | 1 |
| Shilyansky, J | 1 |
| McCray, PB | 1 |
| de Almeida, MB | 1 |
| Zerbinati, RM | 1 |
| Tateno, AF | 1 |
| Oliveira, CM | 1 |
| Romão, RM | 1 |
| Rodrigues, JC | 1 |
| Pannuti, CS | 1 |
| da Silva Filho, LV | 1 |
| Ooi, EH | 1 |
| Psaltis, AJ | 1 |
| Witterick, IJ | 1 |
| Wormald, PJ | 1 |
| Hauber, HP | 4 |
| Lavigne, F | 1 |
| Hung, HL | 1 |
| Levitt, RC | 3 |
| Hamid, Q | 3 |
| Zlosnik, JE | 1 |
| Costa, PS | 1 |
| Brant, R | 1 |
| Mori, PY | 1 |
| Hird, TJ | 1 |
| Fraenkel, MC | 1 |
| Wilcox, PG | 1 |
| Davidson, AG | 1 |
| Speert, DP | 3 |
| Williams, BJ | 1 |
| Dehnbostel, J | 1 |
| Blackwell, TS | 1 |
| Cantón, R | 1 |
| del Campo, R | 1 |
| Dickey, BF | 1 |
| Keicho, N | 1 |
| Hijikata, M | 1 |
| Derichs, N | 1 |
| Jin, BJ | 1 |
| Finkbeiner, WE | 1 |
| Verkman, AS | 2 |
| Wielpütz, MO | 1 |
| Eichinger, M | 2 |
| Zhou, Z | 1 |
| Leotta, K | 1 |
| Bartling, SH | 1 |
| Semmler, W | 1 |
| Kauczor, HU | 2 |
| Puderbach, M | 2 |
| Yang, Y | 1 |
| Tsifansky, MD | 1 |
| Shin, S | 1 |
| Lin, Q | 1 |
| Yeo, Y | 1 |
| Clunes, MT | 1 |
| Cho, HJ | 1 |
| Wu, JV | 3 |
| Irokawa, T | 1 |
| Ianowski, J | 1 |
| Cuthbert, AW | 1 |
| Tran, KV | 1 |
| Thomsson, KA | 1 |
| Pierucci-Alves, F | 1 |
| Akoyev, V | 1 |
| Stewart, JC | 1 |
| Wang, LH | 1 |
| Janardhan, KS | 1 |
| Martens, CJ | 1 |
| Inglis, SK | 3 |
| Valentine, VG | 1 |
| Garrison, J | 1 |
| Conner, GE | 1 |
| O'Clock, GD | 1 |
| Lee, YW | 1 |
| Lee, J | 1 |
| Warwick, WJ | 4 |
| Sankaran, K | 1 |
| Kalapurackal, M | 1 |
| Wiebe, S | 1 |
| Reychler, G | 1 |
| Coppens, T | 1 |
| Leonard, A | 1 |
| Palem, A | 1 |
| Lebecque, P | 1 |
| Reeves, EP | 1 |
| Molloy, K | 1 |
| Pohl, K | 1 |
| Prota, L | 1 |
| Auriemma, G | 1 |
| Crescenzi, C | 1 |
| Porta, A | 1 |
| Ambort, D | 1 |
| Johansson, ME | 1 |
| Nilsson, HE | 1 |
| Thorell, K | 1 |
| Hebert, H | 1 |
| Sjövall, H | 1 |
| Su, S | 1 |
| Hassett, DJ | 4 |
| Kreda, SM | 1 |
| Rose, MC | 2 |
| Zarei, S | 1 |
| Mirtar, A | 1 |
| Rohwer, F | 1 |
| Conrad, DJ | 1 |
| Theilmann, RJ | 1 |
| Salamon, P | 1 |
| Cattoir, V | 1 |
| Narasimhan, G | 1 |
| Skurnik, D | 1 |
| Aschard, H | 1 |
| Roux, D | 1 |
| Ramphal, R | 4 |
| Jyot, J | 2 |
| Lory, S | 3 |
| Cafini, F | 1 |
| García-Rey, C | 1 |
| Bas, P | 1 |
| Gómez-Lus, ML | 1 |
| Sánchez, I | 1 |
| Vázquez, S | 1 |
| Prieto, J | 1 |
| Kondo, M | 1 |
| Tamaoki, J | 1 |
| Puchelle, E | 10 |
| Bajolet, O | 1 |
| Abély, M | 1 |
| Cuppoletti, J | 1 |
| Trapnell, B | 1 |
| Lymar, SV | 2 |
| Rowe, JJ | 1 |
| Hilliard, GM | 1 |
| Parvatiyar, K | 1 |
| Kamani, MC | 1 |
| Wozniak, DJ | 1 |
| Hwang, SH | 2 |
| McDermott, TR | 1 |
| Ochsner, UA | 1 |
| Hirsh, AJ | 3 |
| King, M | 6 |
| Barnes, PJ | 1 |
| Trout, L | 2 |
| Townsley, MI | 1 |
| Bowden, AL | 1 |
| Shibuya, Y | 1 |
| Wills, PJ | 2 |
| Cole, PJ | 4 |
| Manoukian, JJ | 1 |
| Nguyen, LH | 1 |
| Sobol, SE | 1 |
| Holroyd, KJ | 2 |
| Griffin, S | 2 |
| Opdekamp, C | 1 |
| Dawson, M | 1 |
| Wirtz, D | 1 |
| CHERNICK, WS | 1 |
| BARBERO, GJ | 4 |
| EICHEL, HJ | 1 |
| KWART, H | 3 |
| MOSELEY, WW | 1 |
| KATZ, M | 1 |
| TAPPAN, V | 1 |
| ZALAR, V | 1 |
| IACOCCA, VF | 1 |
| SIBINGA, M | 1 |
| MESKIN, LH | 1 |
| BERNARD, B | 1 |
| WEBB, WR | 1 |
| STEIN, AA | 1 |
| MANLAPAS, FC | 1 |
| SOIKE, KF | 1 |
| PATTERSON, PR | 1 |
| DOGGETT, RG | 2 |
| HARRISON, GM | 2 |
| STILLWELL, RN | 1 |
| WALLIS, ES | 1 |
| COZETTO, FJ | 1 |
| COTTON, E | 1 |
| HAIGLER, SH | 1 |
| ASAY, LD | 1 |
| REID, L | 7 |
| POLGAR, G | 1 |
| DENTON, R | 2 |
| Elkins, MR | 3 |
| Jones, A | 2 |
| Schans, C | 1 |
| Henke, MO | 2 |
| Renner, A | 1 |
| Huber, RM | 1 |
| Seeds, MC | 1 |
| Zayas, JG | 1 |
| Mall, M | 1 |
| Harkema, JR | 1 |
| Sajjan, U | 1 |
| Keshavjee, S | 1 |
| Forstner, J | 3 |
| Shale, DJ | 1 |
| Ionescu, AA | 1 |
| Tsicopoulos, A | 1 |
| Wallaert, B | 1 |
| Daigneault, P | 1 |
| Mueller, Z | 1 |
| Olivenstein, R | 1 |
| Zamurs, A | 1 |
| Smith, RT | 1 |
| Paradiso, AM | 2 |
| Hopkins, S | 1 |
| Abraham, WM | 1 |
| Ferrari, S | 1 |
| Shiraki-Iida, T | 1 |
| Shu, T | 1 |
| Hironaka, T | 1 |
| Hou, X | 1 |
| Williams, J | 1 |
| Zhu, J | 1 |
| Jeffery, PK | 1 |
| Geddes, DM | 2 |
| Hasegawa, M | 1 |
| Parnham, MJ | 1 |
| Wilson, SM | 1 |
| Norkina, O | 2 |
| De Lisle, RC | 3 |
| Shah, SA | 1 |
| Santago, P | 1 |
| Matsui, H | 3 |
| Verghese, MW | 1 |
| Schwab, UE | 2 |
| Sheehan, JK | 2 |
| Picher, M | 3 |
| Lazarowski, ER | 1 |
| Fredberg, JJ | 1 |
| Lora, JM | 1 |
| Zhang, DM | 1 |
| Liao, SM | 1 |
| Burwell, T | 1 |
| King, AM | 1 |
| Barker, PA | 1 |
| Singh, L | 1 |
| Keaveney, M | 1 |
| Morgenstern, J | 1 |
| Gutiérrez-Ramos, JC | 1 |
| Coyle, AJ | 1 |
| Fraser, CC | 1 |
| Rogers, TD | 2 |
| Diggs, PC | 1 |
| Parker, JC | 1 |
| Hamm, CR | 1 |
| Roach, EA | 1 |
| Bush, A | 2 |
| Payne, D | 1 |
| Pike, S | 1 |
| Jenkins, G | 1 |
| Coakley, R | 1 |
| Lau, GW | 1 |
| Gaston, B | 1 |
| Karabulut, AC | 1 |
| Hennigan, RF | 1 |
| Buettner, G | 1 |
| Schurr, MJ | 2 |
| Mortensen, JE | 1 |
| Burns, JL | 1 |
| Speert, D | 1 |
| Gendler, SJ | 2 |
| van der Schans, C | 1 |
| Kuver, R | 1 |
| Lee, SP | 1 |
| Gahr, J | 1 |
| Ley, S | 1 |
| Tuengerthal, S | 1 |
| Schmähl, A | 1 |
| Fink, C | 1 |
| Plathow, C | 1 |
| Wiebel, M | 1 |
| Müller, FM | 1 |
| Sonawane, A | 1 |
| During, R | 1 |
| Cakir, E | 1 |
| Uyan, ZS | 1 |
| Ersu, RH | 1 |
| Karadag, B | 1 |
| Karakoc, F | 1 |
| Dagli, E | 1 |
| Judge, EP | 1 |
| Dodd, JD | 1 |
| Masterson, JB | 1 |
| Gallagher, CG | 1 |
| Wagner, VE | 1 |
| Taylor, RM | 1 |
| Iglewski, BH | 1 |
| Donnelly, RF | 1 |
| McCarron, PA | 1 |
| Cassidy, CM | 1 |
| Murray, TS | 1 |
| Egan, M | 1 |
| Kazmierczak, BI | 1 |
| Smith, DJ | 1 |
| Gaffney, EA | 1 |
| Blake, JR | 1 |
| Kadota, J | 1 |
| Palumbo, AA | 1 |
| Luccichenti, G | 1 |
| Belgrano, M | 1 |
| La Grutta, L | 1 |
| Runza, G | 1 |
| Cova, MA | 1 |
| Midiri, M | 1 |
| Grzincich, GL | 1 |
| Battistini, A | 1 |
| Cademartiri, F | 1 |
| de Jonge, HR | 1 |
| Livraghi, A | 1 |
| Homnick, DN | 2 |
| Marks, JH | 2 |
| Bye, PT | 2 |
| Morozov, A | 1 |
| Applegate, KE | 1 |
| Brown, S | 1 |
| Howenstine, M | 1 |
| Roach, E | 1 |
| Jansson, K | 1 |
| Chambers, LA | 1 |
| Rollins, BM | 1 |
| Ianowski, JP | 1 |
| Bingle, L | 1 |
| Barnes, FA | 1 |
| Cross, SS | 1 |
| Rassl, D | 1 |
| Wallace, WA | 1 |
| Campos, MA | 1 |
| Bingle, CD | 1 |
| Moreau-Marquis, S | 1 |
| Stanton, BA | 1 |
| O'Toole, GA | 1 |
| López-Boado, YS | 1 |
| Zabel, P | 1 |
| Hsia, DY | 1 |
| O'Flynn, M | 1 |
| Rowley, WF | 1 |
| Waring, WW | 2 |
| Brunt, CH | 1 |
| Hilman, BC | 1 |
| Litt, M | 2 |
| Roelfs, RE | 1 |
| Gibbs, GE | 1 |
| Griffin, GD | 1 |
| Potter, JL | 2 |
| Matthews, LW | 3 |
| Spector, S | 2 |
| Lemm, J | 2 |
| Di Sant'Agnese, PA | 2 |
| Kulczycki, LL | 1 |
| LoPresti, JM | 1 |
| Lillibridge, CB | 2 |
| Docter, JM | 1 |
| Eidelman, S | 1 |
| Flux, M | 2 |
| Breslow, JL | 1 |
| Phipps, RJ | 1 |
| Davis, PB | 4 |
| Kaliner, M | 1 |
| Ferraris, S | 1 |
| Zannini, G | 1 |
| Romano, C | 1 |
| Gargani, GF | 1 |
| Minicucci, L | 1 |
| Nantron, M | 1 |
| Spicer, SS | 1 |
| Martinez, JR | 1 |
| Wesley, A | 2 |
| Mantle, M | 1 |
| Kopelman, H | 1 |
| Man, D | 1 |
| Forstner, G | 2 |
| Bonforte, RJ | 1 |
| Wanner, A | 4 |
| Simel, DL | 1 |
| Mastin, JP | 1 |
| Pratt, PC | 1 |
| Wisseman, CL | 1 |
| Shelburne, JD | 1 |
| Spock, A | 1 |
| Ingram, P | 1 |
| Newhouse, MT | 2 |
| Ryley, HC | 2 |
| Rennie, D | 1 |
| Bradley, DM | 1 |
| Harding, SE | 2 |
| Rowe, AJ | 1 |
| Creeth, JM | 2 |
| Müller, RM | 2 |
| Roomans, GM | 2 |
| Slayter, HS | 1 |
| Lamblin, G | 8 |
| Le Treut, A | 2 |
| Galabert, C | 4 |
| Houdret, N | 3 |
| Degand, P | 5 |
| Roussel, P | 9 |
| Boersma, A | 2 |
| Klein, A | 1 |
| van Halbeek, H | 2 |
| Vliegenthart, JF | 2 |
| Fletcher, BD | 1 |
| Abramowsky, CR | 1 |
| Lewiston, NJ | 1 |
| Henry, RL | 1 |
| Dorman, DC | 1 |
| Brown, J | 1 |
| Mellis, C | 1 |
| Lukie, BE | 1 |
| Sutton, PP | 1 |
| Lopez-Vidriero, MT | 2 |
| Pavia, D | 1 |
| Newman, SP | 1 |
| Clarke, SW | 1 |
| Frates, RC | 1 |
| Kaizu, TT | 1 |
| Last, JA | 1 |
| Bhaskar, K | 1 |
| Coles, S | 1 |
| Slomiany, A | 3 |
| Slomiany, BL | 3 |
| Witas, H | 1 |
| Aono, M | 1 |
| Newman, LJ | 2 |
| Bang, BG | 2 |
| Bang, FB | 3 |
| Failla, JM | 1 |
| Reynolds, HY | 1 |
| Moriarty, CM | 1 |
| Garett, JS | 1 |
| Fontaine, M | 1 |
| Todisco, T | 1 |
| Grassi, V | 1 |
| Palumbo, R | 1 |
| Bowman, BH | 4 |
| Barnett, DR | 3 |
| Carson, SD | 1 |
| McNeely, MC | 1 |
| Fantoli, U | 1 |
| Scanlin, TF | 1 |
| Fick, RB | 2 |
| Blitzer, MG | 1 |
| Shapira, E | 1 |
| Wesley, AW | 1 |
| Qureshi, AR | 1 |
| Forstner, GG | 1 |
| Forstner, JF | 1 |
| Rossman, CM | 1 |
| Waldes, R | 1 |
| Sampson, D | 1 |
| Dorland, L | 1 |
| Hull, WE | 1 |
| Lhermitte, M | 2 |
| Chow, CW | 1 |
| Landau, LI | 1 |
| Taussig, LM | 1 |
| Fleming, N | 1 |
| Sturgess, JM | 1 |
| Rutland, J | 1 |
| Kennedy, JR | 1 |
| Allen, PL | 1 |
| Kurlandsky, LE | 1 |
| Berninger, RW | 1 |
| Talamo, RC | 1 |
| Smith, SS | 1 |
| Allen, E | 1 |
| Dawson, DC | 1 |
| Wilson, JM | 1 |
| Ambrosino, N | 1 |
| Callegari, G | 1 |
| Galloni, C | 1 |
| Brega, S | 1 |
| Pinna, G | 1 |
| Nishioka, GJ | 1 |
| König, P | 1 |
| Parsons, DS | 1 |
| Cook, PR | 1 |
| Davis, WE | 1 |
| Lundgren, JD | 1 |
| Vestbo, J | 1 |
| Zahm, JM | 7 |
| Jacquot, J | 2 |
| Hinnrasky, J | 1 |
| Fuchey, C | 2 |
| Bettinger, C | 1 |
| Spilmont, C | 1 |
| Bonnet, N | 1 |
| Dieterle, A | 1 |
| Dreyer, D | 1 |
| Pavirani, A | 1 |
| Widdicombe, JG | 1 |
| Deretic, V | 1 |
| Martin, DW | 1 |
| Mudd, MH | 1 |
| Hibler, NS | 1 |
| Curcic, R | 1 |
| Boucher, JC | 1 |
| Girod de Bentzmann, S | 2 |
| Deneuville, E | 1 |
| Perrot-Minnot, C | 1 |
| Dabadie, A | 1 |
| Pennaforte, F | 1 |
| Roussey, M | 1 |
| Shak, S | 1 |
| de Bentzmann, S | 2 |
| Zeman, KL | 1 |
| Carr, DH | 1 |
| Oades, P | 1 |
| Trotman-Dickenson, B | 1 |
| Mohiaddin, R | 1 |
| Wells, AU | 1 |
| Hansen, LG | 1 |
| Hansen, KL | 1 |
| Pierrot, D | 1 |
| Morançais, JL | 1 |
| Montserrat, C | 1 |
| Hollande, E | 1 |
| Guy-Crotte, O | 1 |
| Figarella, C | 1 |
| Bhat, PG | 1 |
| Flanagan, DR | 1 |
| Donovan, MD | 1 |
| Carpenter, LD | 1 |
| Lambie, NK | 1 |
| Wilsher, ML | 1 |
| Jin, S | 2 |
| Boyd, JM | 1 |
| Rakeman, JL | 1 |
| Bergman, P | 1 |
| Roger, P | 1 |
| Luisetti, M | 1 |
| Wang, J | 1 |
| Armengot, M | 1 |
| Escribano, A | 1 |
| Carda, C | 1 |
| Sánchez, C | 1 |
| Romero, C | 1 |
| Basterra, J | 1 |
| Weller, PH | 1 |
| Brihaye, P | 1 |
| Jorissen, M | 1 |
| Clement, PA | 1 |
| Ruzal-Shapiro, C | 1 |
| Feng, W | 2 |
| Garrett, H | 1 |
| Chaffin, A | 1 |
| Chazalette, JP | 1 |
| Grosskopf, C | 1 |
| App, EM | 1 |
| Kieselmann, R | 1 |
| Reinhardt, D | 1 |
| Lindemann, H | 1 |
| Dasgupta, B | 1 |
| Brand, P | 1 |
| Newhouse, PA | 1 |
| White, F | 1 |
| Cohen, JC | 1 |
| Morrow, SL | 1 |
| Cork, RJ | 1 |
| Delcarpio, JB | 1 |
| Larson, JE | 1 |
| Pritchard, K | 1 |
| Parmley, RR | 1 |
| Gatzy, JT | 1 |
| Cockrill, BA | 1 |
| Hales, CA | 1 |
| Kitson, C | 1 |
| Angel, B | 1 |
| Judd, D | 1 |
| Rothery, S | 1 |
| Severs, NJ | 1 |
| Dewar, A | 1 |
| Huang, L | 1 |
| Wadsworth, SC | 1 |
| Cheng, SH | 2 |
| Robinson, M | 1 |
| Eberl, S | 1 |
| Baker, J | 1 |
| Chan, HK | 1 |
| Teramoto, S | 2 |
| Mastsue, T | 1 |
| Ouchi, Y | 1 |
| Banerjee, R | 1 |
| Puniyani, RR | 1 |
| Vastag, B | 1 |
| Singh, PK | 1 |
| Schaefer, AL | 1 |
| Parsek, MR | 1 |
| Greenberg, EP | 1 |
| Marchant, JM | 1 |
| Masel, JP | 1 |
| Dickinson, FL | 1 |
| Masters, IB | 1 |
| Chang, AB | 1 |
| Wegner, CD | 1 |
| Kume, H | 1 |
| Fukuchi, Y | 1 |
| Hudson, VM | 1 |
| Hebestreit, A | 1 |
| Kersting, U | 1 |
| Basler, B | 1 |
| Jeschke, R | 1 |
| Hebestreit, H | 1 |
| Parsons, D | 1 |
| Kirkham, S | 1 |
| Knight, D | 1 |
| Richardson, PS | 1 |
| Worlitzsch, D | 1 |
| Ulrich, M | 1 |
| Cekici, A | 1 |
| Meyer, KC | 1 |
| Birrer, P | 1 |
| Bellon, G | 2 |
| Berger, J | 1 |
| Weiss, T | 1 |
| Botzenhart, K | 1 |
| Randell, S | 1 |
| Döring, G | 1 |
| Saenz, Y | 1 |
| Jayaraman, S | 1 |
| Sanders, NN | 1 |
| De Smedt, SC | 1 |
| Demeester, J | 1 |
| Eggesbø, HB | 1 |
| Søvik, S | 1 |
| Dølvik, S | 1 |
| Kolmannskog, F | 1 |
| Chadburn, JL | 1 |
| Sanjurjo, P | 1 |
| Allue, X | 1 |
| Rodriguez-Soriano, J | 1 |
| Lieberman, J | 1 |
| Foltinová, J | 1 |
| Mikulíková, K | 1 |
| Soltés, L | 1 |
| Conover, JH | 1 |
| Conod, EJ | 1 |
| Oppenheimer, EH | 2 |
| Rosenstein, BJ | 1 |
| Gabridge, MG | 1 |
| Bright, MJ | 1 |
| Agee, CC | 1 |
| Nickerson, JM | 1 |
| Henderson, NS | 1 |
| Mélon, J | 1 |
| Geubelle, F | 1 |
| Lambrechts, L | 1 |
| Leclercq-Fourcart, J | 1 |
| Maréchal, J | 1 |
| Danes, BS | 1 |
| Sutanto, E | 1 |
| Mangos, JA | 1 |
| Neutra, MR | 1 |
| Trier, JS | 1 |
| Shigemoto, H | 1 |
| Endo, S | 1 |
| Isomoto, T | 1 |
| Sano, K | 1 |
| Taguchi, K | 1 |
| Lewis, RW | 1 |
| Wood, RE | 2 |
| Boat, TF | 3 |
| Doershuk, CF | 2 |
| Newhouse, M | 3 |
| Sanchis, J | 2 |
| Bienenstock, J | 1 |
| Govan, JR | 1 |
| Rossman, C | 2 |
| Dodlovich, J | 1 |
| Dodlovich, M | 1 |
| Wilson, W | 2 |
| Wong, JW | 1 |
| Keens, TG | 1 |
| Wannamaker, EM | 1 |
| Crozier, DN | 1 |
| Levison, H | 2 |
| Aspin, N | 1 |
| Lorin, MI | 1 |
| Gaerlan, PF | 1 |
| Mandel, ID | 1 |
| Denning, CR | 1 |
| Cheng, PW | 1 |
| Iyer, RN | 1 |
| Carlson, DM | 2 |
| Polony, I | 1 |
| Dietzsch, HJ | 1 |
| Gottschalk, B | 1 |
| Heyne, K | 1 |
| Leupoid, W | 1 |
| Wunderlich, P | 1 |
| Esterly, JR | 1 |
| Hirsch, J | 1 |
| Farrell, PM | 1 |
| Snouwaert, JN | 1 |
| Brigman, KK | 1 |
| Latour, AM | 1 |
| Malouf, NN | 1 |
| Smithies, O | 1 |
| Koller, BH | 1 |
| Marty, N | 1 |
| Dournes, JL | 1 |
| Chabanon, G | 1 |
| Montrozier, H | 1 |
| Pedersen, SS | 1 |
| Høiby, N | 1 |
| Espersen, F | 1 |
| Koch, C | 1 |
| Dealler, SF | 1 |
| Holton, A | 1 |
| Girod, S | 1 |
| Lecuire, A | 1 |
| Pillai, RS | 1 |
| Chandra, T | 1 |
| Miller, IF | 1 |
| Lloyd-Still, J | 1 |
| Yeates, DB | 1 |
| Umeki, S | 1 |
| Manabe, T | 1 |
| Bataillon, V | 1 |
| Lafitte, JJ | 1 |
| Pommery, J | 1 |
| Lannefors, L | 1 |
| Wollmer, P | 1 |
| Kanamaru, Y | 1 |
| Naziruddin, B | 3 |
| Graves, DC | 2 |
| Reyes de la Rocha, S | 2 |
| Sachdev, GP | 3 |
| Smith, DL | 1 |
| Stableforth, DE | 1 |
| Cushley, M | 1 |
| Desai, VC | 2 |
| Gindzieński, A | 1 |
| Zwierz, K | 1 |
| Nathanson, I | 1 |
| Conboy, K | 1 |
| Murphy, S | 1 |
| Afshani, E | 1 |
| Kuhn, JP | 1 |
| Rutishauser, M | 1 |
| van der Mark, TW | 1 |
| de Vries, G | 1 |
| Piers, DA | 1 |
| Beekhuis, H | 1 |
| Dankert-Roelse, JE | 1 |
| Postma, DS | 1 |
| Koëter, GH | 1 |
| Lethem, MI | 1 |
| James, SL | 1 |
| Marriott, C | 1 |
| Burke, JF | 1 |
| Thiru, S | 2 |
| Devereux, G | 1 |
| King, A | 2 |
| McLeish, M | 1 |
| Baxter, P | 1 |
| Murty, VL | 1 |
| Carter, SR | 2 |
| Gilly, R | 1 |
| Scharfman, A | 1 |
| Perini, JM | 1 |
| Filliat, M | 1 |
| Chace, KV | 1 |
| Rupp, GM | 1 |
| Mawhinney, TP | 1 |
| Adelstein, E | 1 |
| Morris, DA | 1 |
| Mawhinney, AM | 1 |
| Piedra, P | 1 |
| Ogra, PL | 1 |
| Baltimore, RS | 1 |
| Fino, L | 1 |
| Versura, P | 1 |
| Maltarello, MC | 1 |
| Rolando, M | 1 |
| Baldi, F | 1 |
| Calabria, G | 1 |
| van Hengstum, M | 1 |
| Festen, J | 1 |
| Beurskens, C | 1 |
| Hankel, M | 1 |
| Beekman, F | 1 |
| Corstens, F | 1 |
| Matthys, H | 2 |
| Köhler, D | 2 |
| App, E | 1 |
| Schmitz-Schumann, M | 1 |
| Würtemberger, G | 1 |
| Ojeda, VJ | 1 |
| Levitt, S | 1 |
| Ryan, G | 1 |
| Laurence, BH | 1 |
| Quie, PG | 1 |
| Roncoroni, AJ | 1 |
| Greenstone, M | 1 |
| MacLusky, I | 1 |
| McLaughlin, FJ | 1 |
| Wönne, R | 1 |
| Posselt, HG | 1 |
| Stöver, B | 1 |
| Hofmann, D | 1 |
| Bender, SW | 1 |
| Pier, GB | 1 |
| Beck, G | 1 |
| Wooten, MW | 1 |
| Rudick, VL | 1 |
| Rudick, MJ | 1 |
| Higgins, ML | 1 |
| Hein, J | 1 |
| Liau, YH | 1 |
| Carey, JP | 1 |
| Turino, GM | 1 |
| Johansen, PG | 3 |
| Anderson, CM | 2 |
| Hadorn, B | 2 |
| Lev, R | 1 |
| Stoward, PJ | 1 |
| Gibson, LE | 1 |
| Matthews, WJ | 1 |
| Minihan, PT | 1 |
| Jakowska, S | 1 |
| Dudorkinová, D | 1 |
| Lojda, Z | 1 |
| Miller, WF | 2 |
| Johnston, FF | 1 |
| Tarkoff, MP | 1 |
| Bentinck, B | 1 |
| Yeager, H | 1 |
| Gallagher, JT | 1 |
| Marsden, JC | 1 |
| Robards, AW | 1 |
| Racoveanu, C | 1 |
| Nicolaescu, V | 1 |
| Brogan, TD | 1 |
| Allen, L | 1 |
| van Kruiningen, HJ | 1 |
| Williams, CB | 1 |
| Dolovich, M | 1 |
| Sturgess, J | 1 |
| Olivieri, D | 2 |
| Chiefari, M | 1 |
| Capotorti, MA | 1 |
| Marchi, K | 1 |
| Blasi, A | 1 |
| Brown, MR | 1 |
| Hall, JG | 1 |
| Goddard, RF | 1 |
| Mercer, TT | 1 |
| O'Neill, PX | 1 |
| Flores, RL | 1 |
| Sanchez, R | 1 |
| Havez, R | 3 |
| Hartemann, E | 1 |
| Fillat, M | 1 |
| Mayo, J | 1 |
| Yohe, RM | 1 |
| Crifò, S | 1 |
| Antonelli, M | 1 |
| Goldbloom, RG | 1 |
| Rocchietta, S | 1 |
| Morony, T | 1 |
| Bartram, CI | 1 |
| Small, E | 1 |
| Hermier, M | 1 |
| Harteman, E | 1 |
| Khan, MA | 1 |
| Lamb, D | 1 |
| Knauff, RE | 1 |
| Wentworth, P | 1 |
| Gough, J | 1 |
| Wentworth, JE | 1 |
| Nida, KH | 1 |
| Bracken, EC | 1 |
| Saggers, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparisons Effects of Postural Drainage and Positive Expiratory Pressure Technique in Community Acquired Pneumonia.[NCT05356494] | 46 participants (Actual) | Interventional | 2021-09-15 | Completed | |||
| Evaluation of High-Frequency Chest Wall Oscillation Using the Vest Airway Clearance System Compared to Conventional Chest Physical Therapy at Barnes-Jewish Hospital[NCT00717873] | 105 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis[NCT01753869] | 14 participants (Actual) | Interventional | 2012-12-31 | Terminated (stopped due to Challenges with recruitment) | |||
| Double-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and Metabolism[NCT04531410] | 80 participants (Anticipated) | Interventional | 2021-10-25 | Enrolling by invitation | |||
| Evaluation of the Short-term Use of Selected PEP and OPEP Devices in Cystic Fibrosis Patients During an Exacerbation of the Disease[NCT05801952] | 60 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
| Comparison of Two Methods to Airway Clearance in Patients Admitted to Intensive Care Unit for COVID-19: A Pilot Corssover Randomized Controlled Trial[NCT04361435] | 50 participants (Anticipated) | Interventional | 2020-05-01 | Not yet recruiting | |||
| Symptom Based Performance of Airway Clearance Therapy After Starting Highly Effective CFTR Modulator Therapy for Cystic Fibrosis[NCT05392855] | 30 participants (Anticipated) | Interventional | 2023-09-05 | Recruiting | |||
| Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
| Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children With Cystic Fibrosis[NCT04835376] | 25 participants (Actual) | Interventional | 2021-05-01 | Completed | |||
| Repeatability and Response Study of Absorptive Clearance Scans[NCT01887197] | Phase 1 | 24 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Absorptive Clearance in the Cystic Fibrosis Airway[NCT00541190] | 21 participants (Actual) | Interventional | 2007-10-31 | Completed | |||
| Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis[NCT01223183] | Phase 1 | 20 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Imaging Airway Liquid Absorption in Cystic Fibrosis[NCT01486199] | 20 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| "Validation of a Questionnaire to Assess Bronchial Mucus Hypersecretion in Asthmatic Patients. Questionnaire T-sec (Secretion Test)."[NCT05546645] | 100 participants (Anticipated) | Observational | 2023-10-01 | Recruiting | |||
| Gene Modifiers of Cystic Fibrosis Lung Disease[NCT00037765] | 600 participants (Anticipated) | Observational | 2001-09-30 | Active, not recruiting | |||
| [NCT00455130] | Phase 2 | 0 participants | Interventional | 2004-03-31 | Completed | ||
| Bronchial Inflammation of Small Airways in Patients With Cystic Fibrosis[NCT01479166] | 20 participants (Actual) | Observational | 2011-06-30 | Completed | |||
| Role of Cough Assist Device in Mechanically Ventilated Patients in Respiratory Intensive Care Unit : Assiut University Experience[NCT05480371] | 200 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19[NCT04465604] | 50 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| Molekularbiologische Eigenschaften Des Sputums während Einer Pulmonalen COPD Exacerbation[NCT01848093] | 0 participants (Actual) | Observational | 2008-12-31 | Withdrawn | |||
| [NCT00202072] | 25 participants | Observational | 2004-01-31 | Recruiting | |||
| Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis[NCT01031706] | 23 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Effectiveness of Respiratory Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease[NCT02125747] | 35 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| Evaluation of Physiological Responses During the Use of Interactive Video Game and the Cardiopulmonary Exercise Test in Cystic Fibrosis and Healthy Individuals[NCT03229213] | 55 participants (Actual) | Observational | 2017-08-30 | Completed | |||
| Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD[NCT02282202] | 32 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Clinical Evaluation of Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for Symptomatic Relief of Chronic Rhinitis[NCT03727347] | 50 participants (Actual) | Interventional | 2018-10-16 | Completed | |||
| Can High Frequency Chest Wall Oscillation Accelerate the Discharged of Intubated Intensive Care Patients?[NCT02645695] | 30 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Study of the Effect of FLUTTER VRP1 in Patients With Bronchiectasis.[NCT01209546] | Phase 1 | 30 participants (Actual) | Interventional | 2007-07-31 | Terminated (stopped due to The protocol finished.) | ||
| A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis[NCT00117208] | Phase 2 | 20 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study[NCT00630812] | Phase 3 | 318 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Characterization of β-cell Function and Insulin Sensitivity in Pre-transplant Patients With Cystic Fibrosis[NCT04379726] | 150 participants (Anticipated) | Observational | 2020-07-01 | Not yet recruiting | |||
| Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease[NCT04765033] | Phase 4 | 46 participants (Actual) | Interventional | 2021-02-04 | Completed | ||
| Functional and Phenotypic Characteristics of Blood Neutrophils in Cystic Fibrosis[NCT04970225] | 130 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vi[NCT01111383] | Phase 3 | 209 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
an average of 10 days (NCT00717873)
Timeframe: Admission to Discharge
| Intervention | days (Mean) |
|---|---|
| HFCWO Arm | 2.95 |
| CPT Arm | 5.45 |
The absorptive clearance rate is the percentage of the radiolabeled small molecule DTPA that is cleared through absorption over a 60 minute period. Total DTPA clearance includes absorptive and mucociliary components. The mucociliary component is determined by measuring the clearance of a radiolabeled particle over the same period (Technetium 99m sulfur colloid; Tc-SC), and subtracted from total DTPA clearance in order to determine the absorptive component. Here we specifically report absorption from the central lung zone to capture the behavior within the airways. (NCT00541190)
Timeframe: single measurement
| Intervention | percentage of DTPA absoprtion per hour (Mean) |
|---|---|
| Cystic Fibrosis | 42 |
| Healthy Controls | 32 |
"Mucociliary clearance rate represents the rate at which the lungs clear an inhaled particulate. Here it specifically represents the percentage of inhaled Technetium 99m sulfur colloid cleared from the lungs over a 60 minute period. This is reported based on whole lung areas to allow comparisons with previous studies." (NCT00541190)
Timeframe: single measurement
| Intervention | percentage lung clearance per hour (Mean) |
|---|---|
| Cystic Fibrosis | 8 |
| Healthy Controls | 7 |
The absorption rate of In-DTPA after the inhalation of hypertonic saline (NCT01223183)
Timeframe: 80 minutes after radiopharmaceutical inhalation
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| Hypertonic Saline Inhalation | 22.2 |
The absorption rate of Indium 111 diethylenetriaminepentaacetic acid (In-DTPA) in the airways after the inhalation of isotonic saline (NCT01223183)
Timeframe: 80 minutes after radiopharmaceutical inhalation
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| Isotonic Saline Inhalation | 32.0 |
The clearance rate of Tc-SC after the inhalation of hypertonic saline (NCT01223183)
Timeframe: 80 minutes after radiopharmaceutical inhalation
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| Hypertonic Saline Inhalation | 42.4 |
The clearance rate of Tc-SC after the inhalation of isotonic saline (NCT01223183)
Timeframe: 80 minutes after radiopharmaceutical inhalation
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| Isotonic Saline Inhalation | 23.6 |
Absorptive Clearance Rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of In-DTPA from the lungs. (NCT01486199)
Timeframe: t=2 years
| Intervention | percent cleared / 80 min (Mean) |
|---|---|
| CF Pediatric | 28.6 |
Absorptive clearance rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of Indium 111-diethylenetriaminepentaacetic acid (In-DTPA) from the lungs. (NCT01486199)
Timeframe: study day 1
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| CF Pediatric | 34.0 |
| Controls Adult | 17.7 |
Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs. (NCT01486199)
Timeframe: study day 1
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| CF Pediatric | 22.8 |
| Controls Adult | 31.4 |
Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs. (NCT01486199)
Timeframe: t=2 years, measure made 80 minutes after radiopharmaceutical inhalation
| Intervention | percent cleared / 80 minutes (Mean) |
|---|---|
| CF Pediatric | 22.0 |
"Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.~Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC" (NCT01031706)
Timeframe: Baseline versus after completion of 4 week treatment period
| Intervention | percent clearance (Mean) |
|---|---|
| Hypertonic Saline | 2.77 |
| Placebo | -2.35 |
Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated (NCT01031706)
Timeframe: Baseline and after 4 weeks of treatment
| Intervention | Percentage of predicted FEV1 (Mean) |
|---|---|
| Hypertonic Saline | 3.38 |
| Placebo | 1.09 |
"Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value.~The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit" (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure
| Intervention | units on a scale (Mean) |
|---|---|
| InSeca Stylus Treatment Group | -5.1 |
"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity.~The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded." (NCT03727347)
Timeframe: Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Group - Baseline | 8.5 |
| Treatment Group - 2 Week Data | 4.8 |
| Treatment Group - 4 Week Data | 3.6 |
| Treatment Group - 12 Week Data | 3.4 |
| Treatment Group - 26 Week Data | 3.3 |
| Treatment Group - 52 Week Data | 3.6 |
"Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure.~This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure." (NCT03727347)
Timeframe: At or following the study procedure, and up to the final study visit at 1 year.
| Intervention | Participants (Count of Participants) |
|---|---|
| InSeca Stylus Treatment Group | 8 |
"The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected." (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| InSeca Stylus Treatment Group | 46 |
"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity." (NCT03727347)
Timeframe: Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Rhinorrhea | Nasal Congestion | Nasal Itching | Sneezing | |
| Treatment Group - 12 Week Data | 1.0 | 1.1 | 0.5 | 0.9 |
| Treatment Group - 2 Week Data | 1.6 | 1.5 | 0.7 | 1.0 |
| Treatment Group - 26 Week Data | 0.9 | 1.1 | 0.5 | 0.8 |
| Treatment Group - 4 Week Data | 1.2 | 1.1 | 0.4 | 0.8 |
| Treatment Group - 52 Week Data | 1.1 | 1.2 | 0.5 | 0.8 |
| Treatment Group - Baseline | 2.5 | 2.5 | 1.7 | 1.9 |
"This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative.~Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response." (NCT03727347)
Timeframe: The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Section 1, Item 1: Difficulty falling asleep72500892 | Section 1, Item 1: Difficulty falling asleep72500885 | Section 1, Item 1: Difficulty falling asleep72500891 | Section 1, Item 1: Difficulty falling asleep72500893 | Section 1, Item 2: Good sleep throughout the night72500885 | Section 1, Item 2: Good sleep throughout the night72500891 | Section 1, Item 2: Good sleep throughout the night72500892 | Section 1, Item 2: Good sleep throughout the night72500893 | Section 1, Item 3: Feeling fatigued during the day72500885 | Section 1, Item 3: Feeling fatigued during the day72500891 | Section 1, Item 3: Feeling fatigued during the day72500892 | Section 1, Item 3: Feeling fatigued during the day72500893 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500885 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500891 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500892 | Section 1, Item 4: Feelings of frustration/restlessness/irritability72500893 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500885 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500891 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500892 | Section 1, Item 5: Feelings of embarrassment or self-consciousness72500893 | Section 1, Item 6: Having a good sense of overall well-being72500885 | Section 1, Item 6: Having a good sense of overall well-being72500891 | Section 1, Item 6: Having a good sense of overall well-being72500892 | Section 1, Item 6: Having a good sense of overall well-being72500893 | Section 2, Item 1: Oral medications72500885 | Section 2, Item 1: Oral medications72500891 | Section 2, Item 1: Oral medications72500892 | Section 2, Item 1: Oral medications72500893 | Section 2, Item 2: Nasal sprays72500885 | Section 2, Item 2: Nasal sprays72500891 | Section 2, Item 2: Nasal sprays72500892 | Section 2, Item 2: Nasal sprays72500893 | Section 2, Item 3: Nasal breathing strips72500885 | Section 2, Item 3: Nasal breathing strips72500891 | Section 2, Item 3: Nasal breathing strips72500892 | Section 2, Item 3: Nasal breathing strips72500893 | |||||||||||||||||||||||||||||||||||||
| Positive (favorable) response | Neutral or Negative response | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 41 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - Baseline | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 12 Week Data | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 26 Week Data | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment Group - 52 Week Data | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change from baseline at 26 weeks in FEV1 percent predicted with BOCF for those with missing values at week 26 (NCT00630812)
Timeframe: 26 weeks
| Intervention | % of predicted (Least Squares Mean) |
|---|---|
| Mannitol 400mg | 3.14 |
| Control | 0.72 |
Change from baseline in forced expiratory flow at 25-75% of forced vital capacity (FEF25-75) (mL/s) averaged over 26 weeks (measured at 6,14 and 26 weeks) The mean absolute change from baseline over 26 weeks (measured at week 6, 14 and 26) was compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach. Least square means presented are for the average change over the 6, 14, and 26 week visits. (NCT00630812)
Timeframe: 26 weeks
| Intervention | mL/s (Least Squares Mean) |
|---|---|
| Mannitol 400mg | 84.65 |
| Control | 50.31 |
Change from baseline in forced expiratory volume at one second (FEV1) averaged over 26 weeks (measured at 6,14 and 26 weeks) The mean absolute change from baseline FEV1 (mL) over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.Least square means presented are for the average change over the 6, 14, and 26 week visits. (NCT00630812)
Timeframe: 26 weeks
| Intervention | mL (Least Squares Mean) |
|---|---|
| Mannitol 400mg | 106.53 |
| Control | 52.38 |
"In the subset of dornase users, the mean absolute change from baseline FEV1 (mL) averaged over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach. Least square means presented are for the average change over the 6, 14, and 26 week visits.~Change from baseline over 26 weeks (measured at 6,14, 26 weeks) in subset of dornase users" (NCT00630812)
Timeframe: 26 weeks
| Intervention | mL (Least Squares Mean) |
|---|---|
| Mannitol 400mg | 78.60 |
| Control | 35.11 |
Change from baseline in forced vital capacity (FVC) across 26 weeks (measured at 6,14 and 26 weeks) (NCT00630812)
Timeframe: 26 weeks
| Intervention | mL (Least Squares Mean) |
|---|---|
| Mannitol 400mg | 136.33 |
| Control | 64.98 |
Sputum was collected during and for 30 minutes following the administration of the first dose of study treatment. (NCT00630812)
Timeframe: up to 30 mins after first dose of trial treatment
| Intervention | g (Mean) |
|---|---|
| Mannitol 400mg | 4.9 |
| Control | 3.5 |
136 reviews available for guaifenesin and Cystic Fibrosis
| Article | Year |
|---|---|
Role of mucolytics in wet cough.
Topics: Ambroxol; Asthma; Bronchodilator Agents; Cholinergic Antagonists; Cough; Cystic Fibrosis; Expectoran | 2013 |
Physiology and pathophysiology of human airway mucus.
Topics: Cystic Fibrosis; Humans; Lung; Mucociliary Clearance; Mucus; Pulmonary Disease, Chronic Obstructive | 2022 |
Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine!
Topics: Cystic Fibrosis; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive; Sputum | 2022 |
Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: A short review.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Lung; Mucus | 2022 |
[Pneumatic instrumental airway clearance techniques: Description, settings and indications].
Topics: Chest Wall Oscillation; Cystic Fibrosis; Humans; Mucus; Physical Therapy Modalities; Respiratory Phy | 2022 |
Mucus aberrant properties in CF: Insights from cells and animal models.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Lung; Models, Animal; | 2023 |
Mucins and CFTR: Their Close Relationship.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucociliary Clearance; | 2022 |
Synthesis and biomedical applications of mucin mimic materials.
Topics: Cystic Fibrosis; Glycopeptides; Humans; Mucins; Mucus; Polysaccharides | 2022 |
Active cycle of breathing technique for cystic fibrosis.
Topics: Adolescent; Adult; Chest Wall Oscillation; Child; Cystic Fibrosis; Humans; Middle Aged; Mucus; Quali | 2023 |
Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.
Topics: Asthma; Cystic Fibrosis; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive | 2023 |
Mucus, mucins, and cystic fibrosis.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucins; Mucus | 2019 |
Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway.
Topics: Airway Obstruction; Animals; Child; Child, Preschool; Cystic Fibrosis; Disease Models, Animal; Human | 2019 |
Cystic Fibrosis Lung Disease: An Overview.
Topics: Bronchiectasis; Cystic Fibrosis; Humans; Lung; Mucociliary Clearance; Mucus | 2020 |
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis.
Topics: Cystic Fibrosis; Drainage, Postural; Forced Expiratory Volume; Humans; Mucociliary Clearance; Mucus; | 2019 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Chest Wall Oscillation; Child; Cystic Fibrosis; Disease Prog | 2020 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Chest Wall Oscillation; Child; Cystic Fibrosis; Disease Prog | 2020 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Chest Wall Oscillation; Child; Cystic Fibrosis; Disease Prog | 2020 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Chest Wall Oscillation; Child; Cystic Fibrosis; Disease Prog | 2020 |
Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms.
Topics: Arachidonic Acid; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Docosahexaen | 2020 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Chest Wall Oscillation; Child; Cystic Fibrosis; Disease Prog | 2017 |
Bicarbonate in cystic fibrosis.
Topics: Bicarbonates; Chloride-Bicarbonate Antiporters; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu | 2017 |
Autogenic drainage for airway clearance in cystic fibrosis.
Topics: Adolescent; Adult; Aged; Child; Cystic Fibrosis; Drainage, Postural; Exhalation; Forced Expiratory V | 2017 |
Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases.
Topics: Asthma; Cystic Fibrosis; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Histone C | 2018 |
Mucins, Mucus, and Goblet Cells.
Topics: Airway Remodeling; Animals; Cystic Fibrosis; Goblet Cells; Humans; Mucins; Mucociliary Clearance; Mu | 2018 |
Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).
Topics: Animals; Asthma; Bronchiectasis; China; Consensus; Cystic Fibrosis; Drainage; Expectorants; Humans; | 2018 |
Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.
Topics: Animals; Asthma; Cystic Fibrosis; Humans; Mucus; Neuropeptides; Pulmonary Disease, Chronic Obstructi | 2018 |
Inhaled Biologicals for the Treatment of Cystic Fibrosis.
Topics: Administration, Inhalation; alpha 1-Antitrypsin; Animals; Biological Products; Biological Therapy; C | 2019 |
Mucociliary Transport in Healthy and Cystic Fibrosis Pig Airways.
Topics: Animals; Animals, Newborn; Cystic Fibrosis; Disease Models, Animal; Mucociliary Clearance; Mucus; Re | 2018 |
Human Cellular Models for the Investigation of Lung Inflammation and Mucus Production in Cystic Fibrosis.
Topics: Airway Remodeling; Cystic Fibrosis; Humans; Models, Biological; Mucus; Pneumonia; Tissue Engineering | 2018 |
Mucus and mucins in diseases of the intestinal and respiratory tracts.
Topics: Colitis, Ulcerative; Cystic Fibrosis; Humans; Mucins; Mucus; Pulmonary Disease, Chronic Obstructive | 2019 |
Muco-Obstructive Lung Diseases.
Topics: Bronchiectasis; Cilia; Cystic Fibrosis; Disease Progression; Expectorants; Humans; Lung Diseases, Ob | 2019 |
Structure and function of the mucus clearance system of the lung.
Topics: Bronchi; Cystic Fibrosis; Humans; Ion Transport; Lung; Mucus; Physical Therapy Modalities; Respirato | 2013 |
Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis.
Topics: Cough; Cross-Over Studies; Cystic Fibrosis; Drainage, Postural; Humans; Mucus; Percussion; Physical | 2013 |
Sodium channel blockers for cystic fibrosis.
Topics: Amiloride; Anti-Bacterial Agents; Cystic Fibrosis; Forced Expiratory Volume; Humans; Mucus; Randomiz | 2014 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Chest Wall Oscillation; Child; Cystic Fibrosis; Forced Expir | 2014 |
Standard (head-down tilt) versus modified (without head-down tilt) postural drainage in infants and young children with cystic fibrosis.
Topics: Anti-Bacterial Agents; Child, Preschool; Cystic Fibrosis; Disease Progression; Drainage, Postural; G | 2015 |
Therapeutic options for hydrating airway mucus in cystic fibrosis.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mannitol; Muc | 2015 |
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis.
Topics: Chest Wall Oscillation; Cystic Fibrosis; Drainage, Postural; Forced Expiratory Volume; Humans; Mucoc | 2015 |
Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis.
Topics: Cough; Cross-Over Studies; Cystic Fibrosis; Drainage, Postural; Humans; Mucus; Percussion; Physical | 2015 |
Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucus; Nicotiana; Oxid | 2016 |
Mucus Hyperconcentration as a Unifying Aspect of the Chronic Bronchitic Phenotype.
Topics: Bronchitis, Chronic; Cilia; Cystic Fibrosis; Epithelial Cells; Humans; Mucociliary Clearance; Mucus; | 2016 |
Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dehydration; Epitheli | 2016 |
Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis.
Topics: Administration, Inhalation; Bronchitis, Chronic; Cystic Fibrosis; Diuretics, Osmotic; Epithelial Sod | 2016 |
A tale of two sites: how inflammation can reshape the microbiomes of the gut and lungs.
Topics: Anaerobiosis; Colitis; Cystic Fibrosis; Escherichia coli Infections; Feedback, Physiological; Gammap | 2016 |
Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis.
Topics: Bicarbonates; Cystic Fibrosis; Humans; Mucins; Mucus; Pancreas | 2008 |
Airway mucus: the good, the bad, the sticky.
Topics: Cystic Fibrosis; Exocytosis; Gene Expression Regulation; Humans; Lung; Mucins; Mucus; Pulmonary Dise | 2009 |
Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy.
Topics: Animals; Clinical Trials as Topic; Cystic Fibrosis; Expectorants; Gene Transfer Techniques; Genetic | 2009 |
Oscillating devices for airway clearance in people with cystic fibrosis.
Topics: Adolescent; Adult; Breathing Exercises; Child; Cystic Fibrosis; Forced Expiratory Volume; Humans; Lu | 2009 |
Mucins, mucus, and sputum.
Topics: Asthma; Bronchitis, Chronic; Cystic Fibrosis; Female; Humans; Male; Mucins; Mucociliary Clearance; M | 2009 |
Treatment strategies for cystic fibrosis: what's in the pipeline?
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Cond | 2009 |
Mucus, phlegm, and sputum in cystic fibrosis.
Topics: Cystic Fibrosis; Disease Progression; Expectorants; Humans; Mucus; Respiratory Mucosa; Sputum | 2009 |
Airway clearance therapy in cystic fibrosis patients.
Topics: Breathing Exercises; Chest Wall Oscillation; Cystic Fibrosis; Drainage, Postural; Humans; Mucus; Phy | 2009 |
Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
Topics: Administration, Inhalation; Airway Obstruction; Airway Remodeling; Anti-Inflammatory Agents; Child; | 2010 |
The future in paediatric respirology.
Topics: Adult; Asthma; Bronchopulmonary Dysplasia; Child; Chronic Disease; Cystic Fibrosis; Humans; Infant, | 2010 |
Innate immunity.
Topics: Biofilms; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytokines; Homeostas | 2010 |
Pseudomonas aeruginosa: host defence in lung diseases.
Topics: Animals; Biofilms; Bronchiectasis; Bronchiolitis Obliterans; Cross Infection; Cystic Fibrosis; Cytok | 2010 |
Role of epithelial HCO3⁻ transport in mucin secretion: lessons from cystic fibrosis.
Topics: Animals; Bicarbonates; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Airway mucus function and dysfunction.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr | 2010 |
Genetic predisposition to diffuse panbronchiolitis.
Topics: Asia, Eastern; Bronchiolitis; Chromosomes, Human, Pair 6; Cystic Fibrosis; Female; Foam Cells; Genet | 2011 |
[Cystic fibrosis: instrumental airway clearance techniques].
Topics: Airway Resistance; Chest Wall Oscillation; Cystic Fibrosis; Humans; Mucus; Positive-Pressure Respira | 2012 |
Sodium channel blockers for cystic fibrosis.
Topics: Amiloride; Cystic Fibrosis; Humans; Mucus; Randomized Controlled Trials as Topic; Respiration; Salin | 2012 |
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.
Topics: Adolescent; Animals; Anti-Infective Agents; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosi | 2012 |
Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"?
Topics: Biofilms; Cystic Fibrosis; Humans; Mucus; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Cystic fibrosis: the role of the small airways.
Topics: Administration, Inhalation; Aerosols; Animals; Cystic Fibrosis; Humans; Infant; Lung; Mucus; Respira | 2012 |
CFTR, mucins, and mucus obstruction in cystic fibrosis.
Topics: Airway Obstruction; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; D | 2012 |
Effect of inhaled dry powder mannitol on mucus and its clearance.
Topics: Administration, Inhalation; Bronchiectasis; Cystic Fibrosis; Dry Powder Inhalers; Humans; Mannitol; | 2013 |
Regulation of the depth and composition of airway surface liquid.
Topics: Animals; Asthma; Body Water; Bronchitis; Cystic Fibrosis; Ion Channels; Mucus; Respiratory Mucosa; R | 2002 |
An overview of the pathogenesis of cystic fibrosis lung disease.
Topics: Bacterial Infections; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epitheli | 2002 |
Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.
Topics: Alginates; Anaerobiosis; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Chronic Disease; Cysti | 2002 |
Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents.
Topics: Administration, Inhalation; Amiloride; Cystic Fibrosis; Epithelium; Humans; Mannitol; Mucociliary Cl | 2002 |
Pharmacological approaches to discovery and development of new mucolytic agents.
Topics: Cystic Fibrosis; Drug Design; Drug Synergism; Expectorants; Humans; Mucociliary Clearance; Mucus; Re | 2002 |
Regulation of airway surface liquid volume by human airway epithelia.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucus; Respir | 2003 |
Current and future therapies for airway mucus hypersecretion.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Chloride Channels; Cystic Fibrosis; Drug De | 2002 |
[Role of physical therapy in the infant. Role of assistive equipment in the physical therapy of patients with cystic fibrosis].
Topics: Cystic Fibrosis; Drainage, Postural; Humans; Infant; Infant, Newborn; Mucus; Percussion; Physical Th | 2003 |
CYSTIC FIBROSIS.
Topics: Anti-Bacterial Agents; Child; Cystic Fibrosis; Drainage, Postural; Exocrine Glands; Humans; Infant; | 1965 |
Update on pathogenesis of cystic fibrosis lung disease.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ion Transport; Mucus; | 2003 |
New concepts of the pathogenesis of cystic fibrosis lung disease.
Topics: Cystic Fibrosis; Humans; Lung Diseases; Mucus; Respiratory System | 2004 |
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis.
Topics: Cystic Fibrosis; Humans; Mucociliary Clearance; Mucus; Positive-Pressure Respiration; Randomized Con | 2004 |
Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Child; Chronic Disease; Cystic Fibrosis; Humans; Inflammat | 2004 |
Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.
Topics: Anti-Bacterial Agents; Asthma; Bronchiolitis; Cystic Fibrosis; Cytokines; Gene Expression; Humans; I | 2005 |
Cystic fibrosis and airway submucosal glands.
Topics: Cystic Fibrosis; Exocrine Glands; Humans; Hyperplasia; Lung; Mucus | 2005 |
Regulation of airway surface liquid volume and mucus transport by active ion transport.
Topics: Animals; Cystic Fibrosis; Humans; Ion Transport; Mucus; Respiratory Mucosa | 2004 |
Submucosal glands and airway defense.
Topics: Animals; Cystic Fibrosis; Exocrine Glands; Humans; Mucus; Respiratory Mucosa | 2004 |
Regulation of mucin genes in chronic inflammatory airway diseases.
Topics: Animals; Asthma; Cystic Fibrosis; Cytokines; Disease Models, Animal; Gene Expression Regulation; Hum | 2006 |
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis.
Topics: Cystic Fibrosis; Forced Expiratory Volume; Humans; Mucociliary Clearance; Mucus; Positive-Pressure R | 2006 |
Evidence for airway surface dehydration as the initiating event in CF airway disease.
Topics: Aerosols; Animals; Cystic Fibrosis; Dehydration; Humans; Mice; Mice, Transgenic; Models, Animal; Muc | 2007 |
Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Biofilms; Bronchiolitis; Child; Cystic Fibrosis; Humans; Lung; Macrolides; Mu | 2007 |
[Pathophysiology of chronic airway infections].
Topics: Anti-Bacterial Agents; Body Water; Bronchiectasis; Bronchiolitis; Bronchitis, Chronic; Cystic Fibros | 2006 |
Cystic fibrosis and other respiratory diseases of impaired mucus clearance.
Topics: Animals; Cilia; Cystic Fibrosis; Disease Models, Animal; Female; Gene Silencing; Humans; Male; Mice; | 2007 |
Mucus structure and properties in cystic fibrosis.
Topics: Cystic Fibrosis; Humans; Mucociliary Clearance; Mucus; Rheology; Sputum | 2007 |
Other mucoactive agents for cystic fibrosis.
Topics: Cystic Fibrosis; Expectorants; Humans; Ion Transport; Mucus | 2007 |
Liquid movement across the surface epithelium of large airways.
Topics: Animals; Body Fluid Compartments; Chlorides; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembr | 2007 |
Physiology of airway mucus secretion and pathophysiology of hypersecretion.
Topics: Anti-Inflammatory Agents; Asthma; Bronchi; Cystic Fibrosis; Humans; Inhalation Exposure; Intracellul | 2007 |
Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.
Topics: Actins; Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; DNA; Drug Resistance, Bacterial; Epithelia | 2008 |
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
Topics: Animals; Anti-Bacterial Agents; Asthma; Chronic Disease; Cystic Fibrosis; Defensins; Epithelial Cell | 2008 |
Emerging mucus regulating drugs in inflammatory and allergic lung disease.
Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases, Obstructive; Mucins; Mucus; Respiratory System Agent | 2008 |
The airway mucociliary system.
Topics: Animals; Asthma; Autonomic Nervous System; Biological Transport; Bronchi; Bronchitis; Calcium; Cats; | 1981 |
Mucin biosynthesis and secretion in the respiratory tract.
Topics: Animals; Autonomic Nervous System; Cystic Fibrosis; Histocytochemistry; Humans; Irritants; Mucins; M | 1984 |
Abnormal mucus: nominated but not yet elected.
Topics: Albumins; Animals; Cations, Divalent; Cystic Fibrosis; Duodenum; Humans; Intestinal Mucosa; Intestin | 1984 |
Studies of cystic fibrosis utilizing mucociliary activity in oyster gills.
Topics: Animals; Biological Assay; Calcium; Cilia; Cystic Fibrosis; Gills; Mucus; Ostreidae; Proteins | 1980 |
[Changes in tracheobronchial mucociliary clearance].
Topics: Biological Transport; Bronchi; Bronchial Diseases; Cilia; Cystic Fibrosis; Humans; Mucus; Trachea | 1981 |
Cystic fibrosis: current trends in research.
Topics: Cystic Fibrosis; Glycoproteins; Humans; Mucus; Research | 1980 |
Pseudomonas in cystic fibrosis sylph or sycophant?
Topics: Adult; Alginates; Antibody Formation; Cystic Fibrosis; Exotoxins; Humans; Immunity, Cellular; Lung D | 1981 |
Clinical aspects of gastrointestinal mucus.
Topics: Adenocarcinoma; Antigens; Cholelithiasis; Cholera Toxin; Cystic Fibrosis; Digestive System; Gastroen | 1982 |
Accumulation of airway mucus in cystic fibrosis.
Topics: Animals; Bronchi; Chloride Channels; Cystic Fibrosis; Humans; Mucus; Trachea | 1994 |
Regulation of human airway surface liquid.
Topics: Animals; Body Water; Cilia; Cystic Fibrosis; Humans; Ion Transport; Mucociliary Clearance; Mucous Me | 1995 |
Conversion to mucoidy in Pseudomonas aeruginosa.
Topics: Alginates; Cystic Fibrosis; Glucuronic Acid; Hexuronic Acids; Humans; Mucus; Polysaccharides, Bacter | 1993 |
Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.
Topics: Cilia; Cystic Fibrosis; Expectorants; Humans; Mucus; Respiratory System; Rheology; Sodium | 1995 |
Airway goblet cells: responsive and adaptable front-line defenders.
Topics: Animals; Asthma; Bronchitis; Cystic Fibrosis; Exocrine Glands; Humans; Hyperplasia; Mucins; Mucus; P | 1994 |
Mucus transport mechanisms in relation to the effect of high frequency chest compression (HFCC) on mucus clearance.
Topics: Clinical Trials as Topic; Cystic Fibrosis; Drainage, Postural; Gravity Suits; Humans; Lung Diseases, | 1994 |
Pseudomonas aeruginosa adherence to remodelling respiratory epithelium.
Topics: Bacterial Adhesion; Bronchiolitis; Bronchitis; Cystic Fibrosis; Disease Susceptibility; Epithelium; | 1996 |
Role of CFTR gene in the regulation of airway mucus composition.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucus | 1996 |
Implications of early inflammation and infection in cystic fibrosis: a review of new and potential interventions.
Topics: Cystic Fibrosis; Humans; Inflammation; Mucus | 1997 |
Cystic fibrosis. An overview.
Topics: Bile Duct Diseases; Bronchiectasis; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Humans; Lung | 1998 |
Physiological basis of cystic fibrosis: a historical perspective.
Topics: Cystic Fibrosis; Digestive System; Electrolytes; Female; History, 16th Century; History, 17th Centur | 1999 |
Allergic bronchopulmonary aspergillosis.
Topics: Administration, Oral; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Asthma; Bronc | 1999 |
Cystic fibrosis and the salt controversy.
Topics: Bacterial Infections; Body Water; Bronchi; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane | 1999 |
Therapeutic aerosols and airway secretions.
Topics: Aerosols; Animals; Anti-Asthmatic Agents; Asthma; Cystic Fibrosis; Drug Combinations; Fatty Alcohols | 1996 |
Exogenous surfactant therapy and mucus rheology in chronic obstructive airway diseases.
Topics: Animals; Asthma; Bronchitis; Cystic Fibrosis; Humans; Mucociliary Clearance; Mucus; Pulmonary Surfac | 2000 |
Novel mechanistic targets for the treatment of sub-acute and chronic bronchitis.
Topics: Adrenal Cortex Hormones; Antioxidants; Bronchitis; Bronchodilator Agents; Cystic Fibrosis; Humans; I | 2001 |
Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation.
Topics: Antioxidants; Apoptosis; Biological Transport; Contraindications; Cystic Fibrosis; Cystic Fibrosis T | 2001 |
HCO3- transport in relation to mucus secretion from submucosal glands.
Topics: Animals; Bicarbonates; Biological Transport, Active; Cystic Fibrosis; Cystic Fibrosis Transmembrane | 2001 |
Research in cystic fibrosis (third of three parts).
Topics: alpha-Fetoproteins; Animals; Cilia; Cystic Fibrosis; Electrolytes; Endocrine Glands; Female; Heteroz | 1976 |
Recent advances in cystic fibrosis research.
Topics: Adolescent; Adult; Agglutination; Biological Transport; Child; Child, Preschool; Chlorides; Cilia; C | 1976 |
Clinical aspects of mucociliary transport.
Topics: Air Pollutants; Anesthetics; Animals; Asthma; Bronchitis; Chronic Disease; Cilia; Cystic Fibrosis; H | 1977 |
Cystic fibrosis.
Topics: Biological Transport; Cystic Fibrosis; Exocrine Glands; Female; Gastrointestinal Diseases; Genital D | 1976 |
Lung defense mechanisms (first of two parts).
Topics: Airway Obstruction; Animals; Bronchi; Bronchitis; Cilia; Complement System Proteins; Cough; Cystic F | 1976 |
Current biochemical approaches in cystic fibrosis research.
Topics: Biological Transport; Cilia; Cystic Fibrosis; Gastrointestinal Diseases; Glycoproteins; Heterozygote | 1976 |
Introduction: Current investigations and theories on the genetic defect in cystic fibrosis.
Topics: Animals; Cilia; Cystic Fibrosis; Genes; Humans; Mucus; Rabbits | 1976 |
[Structure, function and pathophysiology of mucociliary transport system].
Topics: Cilia; Ciliary Motility Disorders; Cystic Fibrosis; Humans; Mucociliary Clearance; Mucus; Respirator | 1992 |
[Mucus and mucin--biochemical and medical problems].
Topics: Animals; Carbohydrate Sequence; Cystic Fibrosis; Humans; Molecular Sequence Data; Molecular Weight; | 1991 |
[Mucoviscidosis: what is the cause of bronchitis?].
Topics: Acute Disease; Bronchitis; Cystic Fibrosis; Humans; Ion Channels; Mucus; Viscosity | 1988 |
Ciliary function in health and disease.
Topics: Bronchitis; Cilia; Ciliary Motility Disorders; Cystic Fibrosis; Humans; Lung; Lung Diseases, Obstruc | 1985 |
Cystic fibrosis: Part 1.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Blood Proteins; Calgranulin A; Child; Child | 1985 |
Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.
Topics: Adhesiveness; Animals; Antibodies, Bacterial; Antigen-Antibody Complex; Complement System Proteins; | 1985 |
Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
Topics: Adhesiveness; Antibody Formation; Antigen-Antibody Complex; Bacterial Toxins; Blood Bactericidal Act | 1985 |
Hereditary aspects of COPD.
Topics: Adult; Alpha-Globulins; Cystic Fibrosis; Cytoplasm; Female; Heterozygote; Humans; Lung; Lung Disease | 1973 |
Tracheobronchial secretions.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibody Formation; Asthma; Atropine; Bronchi; Bronchitis; Carb | 1971 |
[Normal and pathological bronchial secretion].
Topics: Asthma; Bronchi; Bronchial Diseases; Bronchitis; Chromatography; Cystic Fibrosis; Elasticity; Humans | 1973 |
13 trials available for guaifenesin and Cystic Fibrosis
| Article | Year |
|---|---|
Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial.
Topics: Adult; Cough; Cystic Fibrosis; Forced Expiratory Volume; Humans; Mucociliary Clearance; Mucus | 2022 |
Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies.
Topics: Case-Control Studies; Cilia; Cystic Fibrosis; Granulocytes; Humans; Imaging, Three-Dimensional; Infl | 2019 |
The effectiveness of a mobile high-frequency chest wall oscillation (HFCWO) device for airway clearance.
Topics: Adult; Chest Wall Oscillation; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Lung; Male; Mucu | 2020 |
Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adult; Child; Cross-Over Studies; Cystic Fibrosis; Double-Blind Method; | 2010 |
The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
Topics: Adolescent; Adult; Appetite Stimulants; Child; Cough; Cyproheptadine; Cystic Fibrosis; Double-Blind | 2007 |
[Further study on the possibility of using carbocysteine in cystic fibrosis].
Topics: Carbocysteine; Child; Clinical Trials as Topic; Cysteine; Cystic Fibrosis; Double-Blind Method; Fema | 1983 |
[Controlled clinical study on the activity of a new mucoregulating drug in obstructive bronchial pathology with a marked hypersecretory feature. The pediatric experience].
Topics: Acetylcysteine; Adolescent; Ambroxol; Bromhexine; Bronchial Diseases; Child; Child, Preschool; Clini | 1984 |
Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis.
Topics: Adolescent; Adult; Aerosols; Cilia; Cough; Cystic Fibrosis; Drainage; Humans; Lung; Male; Mucus; Phy | 1982 |
Clinical evaluation of oscillating positive expiratory pressure for enhancing expectoration in diseases other than cystic fibrosis.
Topics: Aged; Bronchiectasis; Bronchitis; Cough; Cystic Fibrosis; Drainage, Postural; Female; Humans; Lung D | 1995 |
Nasal mucociliary transport and ciliary ultrastructure in cystic fibrosis. A comparative study with healthy volunteers.
Topics: Adolescent; Adult; Biological Transport; Child; Child, Preschool; Cilia; Cystic Fibrosis; Disease Su | 1997 |
Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage.
Topics: Adult; Breathing Exercises; Bronchi; Cough; Cross-Over Studies; Cystic Fibrosis; Drainage; Elasticit | 1998 |
The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Topics: Administration, Inhalation; Adolescent; Adult; Bronchi; Cough; Cystic Fibrosis; Female; Forced Expir | 1999 |
The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Topics: Administration, Inhalation; Adolescent; Adult; Bronchi; Cough; Cystic Fibrosis; Female; Forced Expir | 1999 |
The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Topics: Administration, Inhalation; Adolescent; Adult; Bronchi; Cough; Cystic Fibrosis; Female; Forced Expir | 1999 |
The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Topics: Administration, Inhalation; Adolescent; Adult; Bronchi; Cough; Cystic Fibrosis; Female; Forced Expir | 1999 |
A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis.
Topics: Acetylcysteine; Adolescent; Adult; Ambroxol; Bromhexine; Child; Clinical Trials as Topic; Cystic Fib | 1985 |
399 other studies available for guaifenesin and Cystic Fibrosis
| Article | Year |
|---|---|
Need of gastrointestinal surgery in cystic fibrosis? Do not forget the chest!
Topics: Cystic Fibrosis; Digestive System Surgical Procedures; Humans; Mucus | 2021 |
Apparent Yield Stress of Sputum as a Relevant Biomarker in Cystic Fibrosis.
Topics: Adult; Biomarkers; Cystic Fibrosis; Elastic Modulus; Female; Humans; Male; Mucus; Nonlinear Dynamics | 2021 |
Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies.
Topics: Cystic Fibrosis; Diffusion; Humans; Mucus; Permeability; Sputum | 2022 |
Structural lung disease in preschool children with cystic fibrosis: An 18 month natural history study.
Topics: Bronchiectasis; Child; Child, Preschool; Cystic Fibrosis; Humans; Lung; Mucus; Respiratory Function | 2022 |
Cellular and molecular architecture of submucosal glands in wild-type and cystic fibrosis pigs.
Topics: Acinar Cells; Animals; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2022 |
Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Topics: Cystic Fibrosis; Humans; Lung; Mucus; Nanoparticles; Polymers; RNA, Small Interfering; Scattering, S | 2022 |
Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach.
Topics: Cystic Fibrosis; Humans; Mucus; Nanostructures; Physical Therapy Modalities; Sputum | 2022 |
Association Between Evolution of Mucus Plugging, Parenchymal Alterations and Air Trapping on Computed Tomography and Risk of Exacerbations in Adults With Cystic Fibrosis.
Topics: Adult; Cystic Fibrosis; Humans; Mucus; Respiratory Function Tests; Tomography, X-Ray Computed | 2022 |
Elastic mucus strands impair mucociliary clearance in cystic fibrosis pigs.
Topics: Animals; Cystic Fibrosis; Disulfides; Mucociliary Clearance; Mucus; Respiratory Mucosa; Swine | 2022 |
Mucus concentration-dependent biophysical abnormalities unify submucosal gland and superficial airway dysfunction in cystic fibrosis.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Mucus; Respiratory Sy | 2022 |
Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs.
Topics: Cystic Fibrosis; Humans; Lung; Microbiota; Mucus; Tomography, X-Ray Computed | 2021 |
Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis.
Topics: Biomarkers; Child; Child, Preschool; Cystic Fibrosis; DNA; Humans; Mucin 5AC; Mucus; Respiratory Sys | 2022 |
Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence.
Topics: Cystic Fibrosis; Humans; Inflammation; Mucin 5AC; Mucin-5B; Mucus; Proteomics; Respiratory System | 2022 |
Infection and Inflammation MUC up the Cystic Fibrosis Airway.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Inflammation; Mucins; | 2022 |
Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants.
Topics: Cystic Fibrosis; Epithelial Cells; Humans; Lung; Mucus; Nasal Mucosa; Polyps | 2022 |
Effects of Mucin and DNA Concentrations in Airway Mucus on Pseudomonas aeruginosa Biofilm Recalcitrance.
Topics: Biofilms; Cystic Fibrosis; DNA; Humans; Mucins; Mucus; Pseudomonas aeruginosa | 2022 |
Quantity and quality of airway clearance in children and young people with cystic fibrosis.
Topics: Adolescent; Breathing Exercises; Child; Cystic Fibrosis; Forced Expiratory Volume; Humans; Mucus | 2023 |
Proteome of airway surface liquid and mucus in newborn wildtype and cystic fibrosis piglets.
Topics: Animals; Carbachol; Cystic Fibrosis; Goblet Cells; Mucins; Mucus; Proteome; Proteomics; Swine | 2023 |
Cervical mucus quality in females with and without cystic fibrosis.
Topics: Cervix Mucus; Cystic Fibrosis; Female; Humans; Mucociliary Clearance; Mucus | 2023 |
Engineering
Topics: Bacteria; Cystic Fibrosis; Epithelial Cells; Extracellular Traps; Humans; Mucins; Mucus | 2023 |
Modified forced expiration technique using expiratory resistance in adults with cystic fibrosis.
Topics: Adult; Cystic Fibrosis; Humans; Mucus; Physical Therapy Modalities; Positive-Pressure Respiration; R | 2023 |
An ex vivo rat trachea model reveals abnormal airway physiology and a gland secretion defect in cystic fibrosis.
Topics: Animals; Biological Transport; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 2023 |
Niclosamide repurposed for the treatment of inflammatory airway disease.
Topics: Animals; Anoctamins; Anti-Inflammatory Agents; Asthma; Bronchi; Cell Line, Tumor; Cystic Fibrosis; D | 2019 |
Revealing the molecular signaling pathways of mucus stasis in cystic fibrosis.
Topics: Animals; Cystic Fibrosis; Humans; Mice; Mucin 5AC; Mucin-5B; Mucus; Signal Transduction | 2019 |
IL-1β dominates the promucin secretory cytokine profile in cystic fibrosis.
Topics: Animals; Case-Control Studies; Cells, Cultured; Cystic Fibrosis; Female; Gene Expression Regulation; | 2019 |
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; | 2019 |
Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction.
Topics: Administration, Oral; Animals; Arachidonic Acid; Cell Line; Cystic Fibrosis; Disease Models, Animal; | 2020 |
TMEM16A chloride channel does not drive mucus production.
Topics: Anoctamin-1; Biological Transport; Bronchi; Cell Line; Cells, Cultured; Chloride Channels; Cystic Fi | 2019 |
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
Topics: Administration, Inhalation; Animals; Anoctamin-1; Bronchi; Calcium Signaling; Cystic Fibrosis; Cysti | 2020 |
[Mucus buildup: the starting point of cystic fibrosis lung disease pathogenesis].
Topics: Bronchiectasis; Child; Child, Preschool; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu | 2019 |
Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease.
Topics: Adolescent; Bronchi; Bronchiectasis; Child; Cystic Fibrosis; Disease Progression; Female; Forced Exp | 2020 |
Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia.
Topics: Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; H | 2020 |
Structural determinants of long-term functional outcomes in young children with cystic fibrosis.
Topics: Australia; Child; Child, Preschool; Cohort Studies; Cystic Fibrosis; Female; Forced Expiratory Volum | 2020 |
Acid exposure disrupts mucus secretion and impairs mucociliary transport in neonatal piglet airways.
Topics: Acetic Acid; Acid Sensing Ion Channel Blockers; Acid Sensing Ion Channels; Airway Obstruction; Anima | 2020 |
Antibiofilm and mucolytic action of nitric oxide delivered via gas or macromolecular donor using in vitro and ex vivo models.
Topics: Administration, Inhalation; Animals; Biofilms; Chitosan; Cystic Fibrosis; Humans; In Vitro Technique | 2020 |
Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery.
Topics: Cystic Fibrosis; Humans; Lung; Mucus; Nanoparticles; Peptides; Sputum | 2020 |
Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.
Topics: Aminophenols; Animals; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Con | 2020 |
Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery.
Topics: Administration, Inhalation; Cystic Fibrosis; Drug Delivery Systems; Dry Powder Inhalers; Excipients; | 2020 |
Rats Race to Keep Pace in the Growing Cystic Fibrosis Model Space.
Topics: Aminophenols; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Mucus; | 2020 |
Acidic Submucosal Gland pH and Elevated Protein Concentration Produce Abnormal Cystic Fibrosis Mucus.
Topics: Animals; Biological Transport; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 2020 |
Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conduct | 2021 |
Why Airway Gland Secretions Are Abnormally Sticky in Cystic Fibrosis, and Why Not Much Can Be Done About It.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Hydrogen-Ion Concentra | 2020 |
TMEM16A Mediates Mucus Production in Human Airway Epithelial Cells.
Topics: Anoctamin-1; Calcium; Cell Line; Cell Line, Tumor; Chloride Channels; Cystic Fibrosis; Cystic Fibros | 2021 |
Diversity and importance of tracheobronchial glands in mammalian species.
Topics: Animals; Cystic Fibrosis; Exocrine Glands; Mammals; Mucus; Trachea; Tracheitis | 2021 |
Induction of ciliary orientation by matrix patterning and characterization of mucociliary transport.
Topics: Animals; Cattle; Cystic Fibrosis; Epithelial Cells; Humans; Mucociliary Clearance; Mucus | 2021 |
Assisting PNA transport through cystic fibrosis human airway epithelia with biodegradable hybrid lipid-polymer nanoparticles.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Airway Obstruction; Cystic Fibrosis; Cystic Fibrosis Transmembra | 2021 |
Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung Disease.
Topics: Actins; Amino Acid Sequence; Calcium; Catalytic Domain; Conserved Sequence; Cysteine; Cystic Fibrosi | 2021 |
Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult
Topics: Animals; Cathepsins; Cystic Fibrosis; Disease Models, Animal; Epithelial Sodium Channels; Inflammati | 2021 |
New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.
Topics: Animals; Animals, Newborn; Bicarbonates; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance | 2021 |
Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties
Topics: Bicarbonates; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ion Tran | 2022 |
Postnatal Ozone Exposure Disrupts Alveolar Development, Exaggerates Mucoinflammatory Responses, and Suppresses Bacterial Clearance in Developing
Topics: Animals; Bacteria; Cystic Fibrosis; Disease Models, Animal; Epithelial Sodium Channels; Inflammation | 2021 |
Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease.
Topics: Animals; Anoctamin-1; Asthma; Constriction, Pathologic; Cystic Fibrosis; HEK293 Cells; Humans; Infla | 2021 |
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Topics: Animals; Cell Line; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Horses; Humans; Lactic Acid; Mucu | 2017 |
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
Topics: Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Delayed-Action Preparations; Drug Carriers; Li | 2017 |
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections.
Topics: Bronchioles; Cystic Fibrosis; Humans; Lung; Models, Biological; Mucus; Respiratory Tract Infections; | 2017 |
Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: MR Imaging of Airway Mucus Contrasts as a Tool for Diagnosis.
Topics: Adolescent; Adult; Aspergillosis, Allergic Bronchopulmonary; Child; Cystic Fibrosis; Female; Humans; | 2017 |
Roles for Myoepithelial Cells in the Formation and Maintenance of Submucosal Glands.
Topics: Animals; Asthma; Cystic Fibrosis; Epithelial Cells; Exocrine Glands; Humans; Lung; Mucus; Pulmonary | 2017 |
Early Postnatal Secondhand Smoke Exposure Disrupts Bacterial Clearance and Abolishes Immune Responses in Muco-Obstructive Lung Disease.
Topics: Animals; Animals, Newborn; Bacterial Infections; Bacterial Load; Cell Movement; Cystic Fibrosis; Dis | 2017 |
Bronchocele density in cystic fibrosis as an indicator of allergic broncho-pulmonary aspergillosis: A preliminary study.
Topics: Adolescent; Aspergillosis, Allergic Bronchopulmonary; Bronchiectasis; Child; Child, Preschool; Cysti | 2017 |
The innate immune system and beyond.
Topics: Animals; Chronic Disease; Cystic Fibrosis; Humans; Immunity, Innate; Mucociliary Clearance; Mucus; P | 2017 |
Mucus and Cell-Penetrating Nanoparticles Embedded in Nano-into-Micro Formulations for Pulmonary Delivery of Ivacaftor in Patients with Cystic Fibrosis.
Topics: Aminophenols; Cystic Fibrosis; Drug Carriers; Humans; Mucus; Nanoparticles; Quinolones | 2018 |
Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Topics: Cell Line; Colloids; Cystic Fibrosis; Diffusion; Drug Carriers; Drug Compounding; Humans; Hydrophobi | 2018 |
Development of an airway mucus defect in the cystic fibrosis rat.
Topics: Animals; Bicarbonates; Biological Transport; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta | 2018 |
Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms.
Topics: Biofilms; Cystic Fibrosis; Lipids; Mucus; Nanoparticles | 2018 |
Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients.
Topics: Amikacin; Bacterial Infections; Cystic Fibrosis; Drug Delivery Systems; Drug Liberation; Emulsions; | 2018 |
PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Chickens; Cystic Fibrosis; Humans; Lung; Microbial Sensiti | 2018 |
Pseudomonas aeruginosa pyocyanin production reduced by quorum-sensing inhibiting nanocarriers.
Topics: Cystic Fibrosis; Drug Carriers; Humans; Mucus; Nanoparticles; Polymers; Pseudomonas aeruginosa; Pyoc | 2018 |
PLCB3 Loss of Function Reduces Pseudomonas aeruginosa-Dependent IL-8 Release in Cystic Fibrosis.
Topics: Bronchi; Calcium Signaling; Cell Line; Computer Simulation; Cystic Fibrosis; Humans; Interleukin-8; | 2018 |
Persistent Atelectasis in a Patient With Cystic Fibrosis: Are Antibiotics Always Needed?
Topics: Adolescent; Adrenal Cortex Hormones; Airway Obstruction; Anti-Bacterial Agents; Antifungal Agents; C | 2019 |
The mucus bundles responsible for airway cleaning are retained in cystic fibrosis and by cholinergic stimulation.
Topics: Animals; Cholinergic Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; D | 2018 |
Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
Topics: Anti-Bacterial Agents; Biofilms; Burkholderia cepacia complex; Cystic Fibrosis; Drug Carriers; Human | 2018 |
Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Anima | 2019 |
A clean sweep: mucin bundles clear the airway.
Topics: Cholinergic Agents; Cystic Fibrosis; Humans; Mucins; Mucus; Respiratory System | 2018 |
Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs.
Topics: Animals; Bacteria; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Disease Models, Animal; Epithelial | 2018 |
An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
Topics: Acetylcysteine; Animals; Asthma; Cystic Fibrosis; Disease Models, Animal; Dithiothreitol; Expectoran | 2019 |
Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model.
Topics: Animals; Biological Transport; Cystic Fibrosis; Drug Carriers; Mucins; Mucus; Peptide Library; Pepti | 2018 |
Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH.
Topics: Adolescent; Adult; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Hum | 2018 |
Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats.
Topics: Actins; Animals; Cystic Fibrosis; Epididymis; Female; Male; Mucus; Pregnancy; Rats; Vas Deferens | 2019 |
Roles of mucus adhesion and cohesion in cough clearance.
Topics: Bicarbonates; Cell Adhesion; Cough; Cystic Fibrosis; Epithelial Cells; Humans; Hydrogen-Ion Concentr | 2018 |
Dropping acid: why is cystic fibrosis mucus abnormal?
Topics: Cystic Fibrosis; Humans; Hydrogen-Ion Concentration; Mucus; Viscosity | 2018 |
Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier.
Topics: A549 Cells; Adult; Biocompatible Materials; Cell Proliferation; Chromatography, High Pressure Liquid | 2019 |
Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis.
Topics: Animals; Cattle; Cell Survival; Cystic Fibrosis; DNA; Drug Delivery Systems; Emulsions; Escherichia | 2019 |
Targeting of cathepsin S reduces cystic fibrosis-like lung disease.
Topics: Airway Obstruction; Animals; Cathepsins; Cystic Fibrosis; Disease Models, Animal; Epithelial Sodium | 2019 |
CT evaluation of hyperattenuating mucus to diagnose allergic bronchopulmonary aspergillosis in the special condition of cystic fibrosis.
Topics: Adolescent; Aspergillosis, Allergic Bronchopulmonary; Child; Cystic Fibrosis; Humans; Mucus; Retrosp | 2019 |
Mucus penetrating properties of soft, distensible lipid nanocapsules.
Topics: Animals; Cystic Fibrosis; Diffusion; Drug Liberation; Gastric Mucosa; Humans; Lipids; Mucins; Mucus; | 2019 |
Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study.
Topics: A549 Cells; Anti-Bacterial Agents; Cell Survival; Cystic Fibrosis; Delayed-Action Preparations; Drug | 2019 |
Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Topics: Anti-Bacterial Agents; Biofilms; Cell Line; Cystic Fibrosis; Drug Carriers; Humans; Mucus; Nanoparti | 2019 |
Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.
Topics: Animals; Biomarkers; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; | 2019 |
A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Anima | 2019 |
Exercising our options: comparing effects of exercise and positive expiratory pressure on mucociliary clearance.
Topics: Cross-Over Studies; Cystic Fibrosis; Forced Expiratory Volume; Humans; Mucociliary Clearance; Mucus | 2019 |
Influence of frequency and amplitude on the mucus viscoelasticity of the novel mechano-acoustic Frequencer™.
Topics: Acoustics; Animals; Cystic Fibrosis; Drainage, Postural; Humans; Mechanical Phenomena; Mucus; Physic | 2019 |
Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powders.
Topics: Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Calorimetry, Differential Scann | 2013 |
Inhalable DNase I microparticles engineered with biologically active excipients.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Aerosols; Animals; Chitosan; Cystic | 2013 |
Evidence for sigma factor competition in the regulation of alginate production by Pseudomonas aeruginosa.
Topics: Alginates; Blotting, Western; Cystic Fibrosis; DNA Transposable Elements; DNA-Directed RNA Polymeras | 2013 |
Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways.
Topics: Adult; Analysis of Variance; Cells, Cultured; Crystallization; Cystic Fibrosis; Dehydration; Epithel | 2013 |
Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa.
Topics: Child; Cough; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Lung; Male; Mucociliary Cle | 2014 |
A new method to improve the clinical evaluation of cystic fibrosis patients by mucus viscoelastic properties.
Topics: Adult; Bacterial Infections; Cystic Fibrosis; Elasticity; Forced Expiratory Volume; Humans; Middle A | 2014 |
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.
Topics: Administration, Intranasal; Adult; Animals; CHO Cells; Cricetulus; Cystic Fibrosis; Cystic Fibrosis | 2014 |
A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.
Topics: Adult; Aged; Biomarkers; Cystic Fibrosis; Diffusion; Disease Progression; Elasticity; Fourier Analys | 2014 |
Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets.
Topics: Aging; Animals; Atrophy; Bacteria; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2014 |
Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.
Topics: Airway Obstruction; Animals; Bronchiectasis; Cystic Fibrosis; Disease Models, Animal; Epithelial Sod | 2014 |
Mucociliary clearance and submucosal gland secretion in the ex vivo ferret trachea.
Topics: Analgesics, Non-Narcotic; Angiogenesis Inhibitors; Animals; Bronchodilator Agents; Bumetanide; Calci | 2014 |
Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema.
Topics: Airway Obstruction; Animals; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Dehydration; Genomics; M | 2014 |
Medicine. Letting go of mucus.
Topics: Animals; Cystic Fibrosis; Exocrine Glands; Mucociliary Clearance; Mucus; Respiratory Mucosa; Respira | 2014 |
Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis.
Topics: Animals; Animals, Newborn; Anions; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance | 2014 |
Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis.
Topics: Animals; Animals, Newborn; Anions; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance | 2014 |
Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis.
Topics: Animals; Animals, Newborn; Anions; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance | 2014 |
Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis.
Topics: Animals; Animals, Newborn; Anions; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance | 2014 |
Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus.
Topics: Burkholderia cepacia; Burkholderia Infections; Culture Media; Cystic Fibrosis; Humans; Lung; Mucus; | 2014 |
Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function.
Topics: Adenosine Triphosphate; Cell Survival; Cells, Cultured; Cilia; Cyanides; Cystic Fibrosis; Healthy Vo | 2014 |
Hypertonic saline releases the attached small intestinal cystic fibrosis mucus.
Topics: Animals; Cystic Fibrosis; Female; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2015 |
Oxidation increases mucin polymer cross-links to stiffen airway mucus gels.
Topics: Acetylcysteine; Animals; Biomechanical Phenomena; Cross-Linking Reagents; Cystic Fibrosis; Disulfide | 2015 |
Model of mucociliary clearance in cystic fibrosis lungs.
Topics: Administration, Inhalation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; De | 2015 |
The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology.
Topics: Activins; Adult; Animals; Body Weight; Cystic Fibrosis; Disease Models, Animal; Female; Follistatin; | 2015 |
Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.
Topics: Administration, Inhalation; Animals; Cystic Fibrosis; DNA; Genetic Therapy; Mice; Mucus; Nanoparticl | 2015 |
Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.
Topics: Animals; Bicarbonates; Calcium Chelating Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Cond | 2015 |
Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier.
Topics: Cystic Fibrosis; Expectorants; Gene Transfer Techniques; Genetic Therapy; Humans; Inflammation; Infl | 2015 |
Pharmacological rescue of mutant CFTR protein improves the viscoelastic properties of CF mucus.
Topics: Amiloride; Aminopyridines; Benzodioxoles; Biological Availability; Cell Culture Techniques; Cystic F | 2016 |
Acidic pH increases airway surface liquid viscosity in cystic fibrosis.
Topics: Alveolar Epithelial Cells; Animals; Bicarbonates; Carbohydrate Sequence; Cells, Cultured; Cystic Fib | 2016 |
A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease.
Topics: Adolescent; Adult; Alginates; Animals; Chronic Disease; Clinical Trials, Phase I as Topic; Cystic Fi | 2016 |
Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor.
Topics: Aminophenols; Child; Cystic Fibrosis; Duodenum; Humans; Mucus; Quinolones; Treatment Outcome | 2016 |
Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus.
Topics: Cell Line; Cystic Fibrosis; Humans; Ibuprofen; Mucus; Nanoparticles; Peptides; Polyesters; Polyethyl | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Topics: Administration, Inhalation; Adult; Aerosols; Cystic Fibrosis; Disease Progression; Female; Humans; L | 2016 |
A parametric study of mucociliary transport by numerical simulations of 3D non-homogeneous mucus.
Topics: Cilia; Computer Simulation; Cystic Fibrosis; Lung; Models, Biological; Mucociliary Clearance; Mucus; | 2016 |
A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice.
Topics: Alginates; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gastrointe | 2016 |
IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection.
Topics: Animals; Chronic Disease; Cystic Fibrosis; Disease Models, Animal; Interleukin-22; Interleukins; Lun | 2016 |
Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis.
Topics: Adrenergic beta-Agonists; Adult; Amiloride; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan | 2016 |
Particle-Tracking Microrheology Using Micro-Optical Coherence Tomography.
Topics: Bronchi; Cells, Cultured; Computer Simulation; Cystic Fibrosis; Dextrans; Epithelial Cells; Humans; | 2016 |
Microstructural alterations of sputum in cystic fibrosis lung disease.
Topics: Cystic Fibrosis; Deoxyribonuclease I; Humans; Lung; Mucus; Recombinant Proteins; Respiratory Therapy | 2016 |
Study suggests hidden epidemic in CF patients.
Topics: Cross Infection; Cystic Fibrosis; Epidemics; Equipment Contamination; Humans; Mucus; Mycobacterium; | 2016 |
Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Drug Carriers; Drug Liberation; Epithelial Cells; | 2017 |
Toll-like receptor activation by sino-nasal mucus in chronic rhinosinusitis.
Topics: Adult; Aged; Aged, 80 and over; Cystic Fibrosis; Cytokines; Female; Humans; Male; Middle Aged; Mucus | 2017 |
Identification of essential genes of Pseudomonas aeruginosa for its growth in airway mucus.
Topics: Bacterial Proteins; Culture Media; Cystic Fibrosis; DNA Transposable Elements; Drug Discovery; Gene | 2017 |
A Model for the Transient Subdiffusive Behavior of Particles in Mucus.
Topics: Cystic Fibrosis; Diffusion; Humans; Lung; Models, Biological; Movement; Mucus; Nanoparticles; Polyet | 2017 |
Numerical and experimental investigation of mucociliary clearance breakdown in cystic fibrosis.
Topics: Cystic Fibrosis; Humans; Lung; Models, Biological; Mucociliary Clearance; Mucus; Rheology; Viscosity | 2017 |
OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium.
Topics: Alginates; Animals; Calcium; Chelating Agents; Cystic Fibrosis; Glucuronic Acid; Hexuronic Acids; Il | 2017 |
Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity.
Topics: ABO Blood-Group System; Adolescent; Adult; Blood Group Antigens; Cystic Fibrosis; Female; Genetic Pr | 2009 |
Substance P stimulates human airway submucosal gland secretion mainly via a CFTR-dependent process.
Topics: Age Factors; Animals; Calcium Signaling; Capsicum; Carbachol; Chelating Agents; Clotrimazole; Colfor | 2009 |
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.
Topics: Analysis of Variance; Biological Transport; Cells, Cultured; Chlorides; Cystic Fibrosis; Cystic Fibr | 2009 |
Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Bronchitis; Child, Preschool; Cystic Fibrosis; Expectora | 2009 |
Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Bicarbonates; Bumetanide; Cystic Fibrosis | 2009 |
Birth of mucus.
Topics: Animals; Bicarbonates; Biological Transport; Calcium; Cystic Fibrosis; Fetus; Humans; Mucins; Mucus | 2010 |
Pathology of gastrointestinal organs in a porcine model of cystic fibrosis.
Topics: Animals; Cell Proliferation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; D | 2010 |
Lipids control mucus production in cystic fibrosis.
Topics: Animals; Carbonic Anhydrase II; Carbonic Anhydrase IV; Cystic Fibrosis; Cystic Fibrosis Transmembran | 2010 |
Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.
Topics: Animals; Animals, Newborn; Cystic Fibrosis; Disease Models, Animal; Ileus; Inflammation; Lung; Mecon | 2010 |
Rhinovirus C and respiratory exacerbations in children with cystic fibrosis.
Topics: Adolescent; Brazil; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Male; Molecula | 2010 |
Effect of Th2 type cytokines on hCLCA1 and mucus expression in cystic fibrosis airways.
Topics: Cells, Cultured; Chloride Channels; Cystic Fibrosis; Cytokines; Female; Humans; Male; Mucin 5AC; Muc | 2010 |
Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections.
Topics: Adolescent; Adult; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Disease P | 2011 |
Cystic fibrosis: deciphering the complexity.
Topics: Bacterial Infections; Candida albicans; Chromosomes, Human, Pair 7; Cystic Fibrosis; Cystic Fibrosis | 2010 |
Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching.
Topics: Amiloride; Bronchi; Cells, Cultured; Cilia; Colforsin; Cystic Fibrosis; Cystic Fibrosis Transmembran | 2011 |
In vivo monitoring of cystic fibrosis-like lung disease in mice by volumetric computed tomography.
Topics: Airway Obstruction; Animals; Bronchography; Cone-Beam Computed Tomography; Cystic Fibrosis; Disease | 2011 |
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Hu | 2011 |
Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.
Topics: Airway Remodeling; Animals; Bacterial Infections; Biofilms; Biological Transport; Cystic Fibrosis; C | 2011 |
Measurement of fluid secretion from intact airway submucosal glands.
Topics: Animals; Biological Transport; Body Fluids; Cats; Cystic Fibrosis; Cystic Fibrosis Transmembrane Con | 2011 |
Identification and quantification of mucin expression.
Topics: Alcian Blue; Animals; Antibodies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulat | 2011 |
Swine models of cystic fibrosis reveal male reproductive tract phenotype at birth.
Topics: Animals; Animals, Genetically Modified; Animals, Newborn; Anions; Chloride-Bicarbonate Antiporters; | 2011 |
Mucous solids and liquid secretion by airways: studies with normal pig, cystic fibrosis human, and non-cystic fibrosis human bronchi.
Topics: Animals; Anions; Bronchi; Cystic Fibrosis; Humans; In Vitro Techniques; Models, Biological; Mucus; O | 2011 |
High-frequency and low-frequency chest compression: effects on lung water secretion, mucus transport, heart rate, and blood pressure using a trapezoidal source pressure waveform.
Topics: Biological Transport, Active; Blood Pressure; Body Water; Chest Wall Oscillation; Computer Simulatio | 2012 |
Cystic fibrosis: an unusual neonatal presentation.
Topics: Cystic Fibrosis; Female; Humans; Infant, Newborn; Mucus; Pulmonary Atelectasis; Respiratory Distress | 2012 |
Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?
Topics: Administration, Inhalation; Anti-Infective Agents; Cystic Fibrosis; Gentamicins; Leucine; Microbial | 2013 |
Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype.
Topics: Animals; Bicarbonates; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Re | 2012 |
Mucus distribution model in a lung with cystic fibrosis.
Topics: Adolescent; Adult; Aged; Algorithms; Biofilms; Computer Simulation; Cystic Fibrosis; Disease Progres | 2012 |
Transcriptional response of mucoid Pseudomonas aeruginosa to human respiratory mucus.
Topics: Bacterial Proteins; Cystic Fibrosis; Humans; Mucus; Pseudomonas aeruginosa; Pseudomonas Infections; | 2013 |
[Discrepancy in the disk diffusion susceptibility test of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients after anaerobic preincubation and its potential clinical relevance].
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Cystic Fibrosis; Disk Diffusion Antimicrobial Tests | 2012 |
[The cutting-edge of medicine; Management and therapy for airway mucus hypersecretion].
Topics: Asthma; Bronchiolitis Obliterans; Cystic Fibrosis; Humans; Mucus; Pulmonary Disease, Chronic Obstruc | 2012 |
Airway mucus in cystic fibrosis.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucins; Mucociliary Cl | 2002 |
Disruptive effects of anion secretion inhibitors on airway mucus morphology in isolated perfused pig lung.
Topics: Adrenergic beta-Agonists; Algorithms; Amiloride; Animals; Anions; Bethanechol; Bicarbonates; Bronchi | 2003 |
Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
Topics: Bronchiectasis; Cystic Fibrosis; Elasticity; Humans; Mucociliary Clearance; Mucus; Osmolar Concentra | 2003 |
Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis.
Topics: Biopsy; Chloride Channels; Cystic Fibrosis; Epithelial Cells; Humans; Immunoenzyme Techniques; Inter | 2003 |
Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport.
Topics: Adolescent; Adult; Biological Transport; Carbon; Cystic Fibrosis; Deoxyribonuclease I; Deoxyribonucl | 2003 |
In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients withcystic fibrosis.
Topics: Cystic Fibrosis; Exudates and Transudates; Humans; Mucus; Peptide Hydrolases | 1961 |
The chemical characterization of human tracheobronchial secretion: a possible clue to the orgin of fibrocystic mucus.
Topics: Cystic Fibrosis; DNA; Exudates and Transudates; Humans; Mucus; Sputum | 1963 |
The pathophysiology of bronchial mucus.
Topics: Bronchi; Cystic Fibrosis; Deoxyribonuclease I; Exudates and Transudates; Glycosaminoglycans; Humans; | 1963 |
RESPIRATORY TRACT BACTERIOLOGY IN CYSTIC FIBROSIS.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacteriology; Child; Cystic Fibrosis | 1963 |
BIOPSY OF THE LABIAL MUCOUS SALIVARY GLANDS IN CYSTIC FIBROSIS.
Topics: Biopsy; Child; Cystic Fibrosis; Electrons; Histocytochemistry; Humans; Lip; Microscopy; Microscopy, | 1964 |
NEW MUCOLYTIC AGENTS FOR SPUTUM LIQUEFACTION.
Topics: Acetylcysteine; Asthma; Bronchial Diseases; Cysteine; Cystic Fibrosis; Expectorants; Fibrin; Humans; | 1964 |
SPECIFIC ISOANTIBODIES IN CYSTIC FIBROSIS. A STUDY OF SERUM AND BRONCHIAL MUCUS.
Topics: Adolescent; Antigen-Antibody Reactions; Autoantibodies; Blood; Child; Cystic Fibrosis; Humans; Immun | 1964 |
ENZYMATIC ACTION ON THE CAPSULAR MATERIAL PRODUCED BY PSEUDOMONAS AERUGINOSA OF CYSTIC FIBROSIS ORIGIN.
Topics: Amylases; Chemical Phenomena; Chemistry; Cystic Fibrosis; Humans; Mucoproteins; Mucus; Pseudomonas a | 1965 |
CYSTIC FIBROSIS.
Topics: Cystic Fibrosis; Diagnosis, Differential; Genetics, Medical; Humans; Mucus | 1965 |
HISTOCHEMICAL AND ENZYME STUDIES OF BRONCHIAL MUCUS.
Topics: Asthma; Bronchi; Bronchitis; Cystic Fibrosis; Glycosaminoglycans; Histocytochemistry; Humans; Mucous | 1965 |
Cystic fibrosis in adults. Studies of pulmonary function and some physical properties of bronchial mucus.
Topics: Adult; Cystic Fibrosis; Humans; Lung; Mucus; Pulmonary Fibrosis; Respiration | 1962 |
MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.
Topics: Adolescent; Adult; Bronchi; Bronchitis; Child; Cystic Fibrosis; DNA; Down-Regulation; Female; Glycop | 2004 |
MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.
Topics: Adolescent; Adult; Bronchi; Bronchitis; Child; Cystic Fibrosis; DNA; Down-Regulation; Female; Glycop | 2004 |
MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.
Topics: Adolescent; Adult; Bronchi; Bronchitis; Child; Cystic Fibrosis; DNA; Down-Regulation; Female; Glycop | 2004 |
MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.
Topics: Adolescent; Adult; Bronchi; Bronchitis; Child; Cystic Fibrosis; DNA; Down-Regulation; Female; Glycop | 2004 |
Mucomodulator therapy in cystic fibrosis: balancing mucus clearability against the spread of airborne pathogens.
Topics: Cystic Fibrosis; Expectorants; Humans; Mucociliary Clearance; Mucus | 2004 |
Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Anima | 2004 |
Responses of well-differentiated airway epithelial cell cultures from healthy donors and patients with cystic fibrosis to Burkholderia cenocepacia infection.
Topics: Burkholderia; Burkholderia Infections; Cystic Fibrosis; Cytokines; Epithelial Cells; Fluorescent Ant | 2004 |
Mucus hypersecretion: a common symptom, a common mechanism?
Topics: Asthma; Chloride Channels; Cystic Fibrosis; Humans; Inflammation; Interleukin-9; Mucus; Receptors, I | 2004 |
Expression of HCLCA1 in cystic fibrosis lungs is associated with mucus overproduction.
Topics: Case-Control Studies; Chloride Channels; Cystic Fibrosis; Humans; Immunohistochemistry; In Situ Hybr | 2004 |
Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
Topics: Absorption; Amiloride; Animals; Bronchi; Cystic Fibrosis; Electrophysiology; Epithelial Cells; Epith | 2004 |
A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo.
Topics: Adult; Animals; beta-Galactosidase; Cells, Cultured; Cystic Fibrosis; Female; Gene Deletion; Gene Ex | 2004 |
Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10.
Topics: Animals; Body Weight; Chromosomes, Mammalian; Cystic Fibrosis; Female; Genetic Markers; Inflammation | 2005 |
Quantification of biopolymer filament structure.
Topics: Actins; Algorithms; Biopolymers; Child; Cystic Fibrosis; DNA; Humans; Image Processing, Computer-Ass | 2005 |
Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces.
Topics: Bronchi; Cell Line; Cell Migration Inhibition; Chemotaxis, Leukocyte; Cilia; Cystic Fibrosis; Desicc | 2005 |
Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections.
Topics: Adenosine; Adenosine Triphosphatases; Adenosine Triphosphate; Adolescent; Adult; Biological Transpor | 2005 |
Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism.
Topics: Active Transport, Cell Nucleus; Adenoviridae; Animals; beta-Galactosidase; Cell Line; Cell Line, Tum | 2005 |
Culture of murine nasal epithelia: model for cystic fibrosis.
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cystic Fibrosis; Disease Models, Animal; Ele | 2006 |
Restoration of mucociliary transport in the fluid-depleted trachea by surface-active instillates.
Topics: Animals; Biological Products; Cystic Fibrosis; In Vitro Techniques; Instillation, Drug; Mucociliary | 2006 |
Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation.
Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Cystic Fibrosis Transmembr | 2006 |
Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis.
Topics: Biomarkers; Child; Cystic Fibrosis; Elasticity; Humans; Interleukin-8; Kartagener Syndrome; Mucus; R | 2006 |
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.
Topics: Anaerobiosis; Animals; Bacterial Proteins; Biofilms; Cells, Cultured; Child; Child, Preschool; Cysti | 2006 |
Hypertonic saline for cystic fibrosis.
Topics: Administration, Inhalation; Calcium; Cystic Fibrosis; Humans; Mucins; Mucociliary Clearance; Mucus; | 2006 |
Proton MRI appearance of cystic fibrosis: comparison to CT.
Topics: Adolescent; Adult; Bronchi; Bronchography; Child; Cystic Fibrosis; Female; Humans; Magnetic Resonanc | 2007 |
Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa.
Topics: Cell Extracts; Cystic Fibrosis; Flagellin; Hot Temperature; Humans; Immunity, Innate; Leukocyte Elas | 2006 |
Mucoid impaction: an unusual form of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Cataract; Chil | 2006 |
Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis.
Topics: Adolescent; Adult; Analysis of Variance; Bronchiectasis; Cystic Fibrosis; Female; Forced Expiratory | 2006 |
A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.
Topics: Biofilms; Cells, Cultured; Chemical Phenomena; Chemistry, Physical; Cystic Fibrosis; Gels; Humans; M | 2006 |
Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection.
Topics: Cystic Fibrosis; Diffusion; Humans; Light; Microbial Viability; Mucus; Photochemotherapy; Photosensi | 2007 |
A model of tracer transport in airway surface liquid.
Topics: Biological Transport; Cilia; Cystic Fibrosis; Fluorescent Dyes; Humans; Lung; Models, Biological; Mu | 2007 |
Three-dimensional quantitative assessment of lung parenchyma in cystic fibrosis: preliminary results.
Topics: Adolescent; Algorithms; Bronchi; Bronchiectasis; Bronchography; Cineradiography; Cystic Fibrosis; Da | 2007 |
Cystic fibrosis mice rehabilitated for studies of airway gland dysfunction.
Topics: Animals; Cyclic GMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Exocrine | 2007 |
Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia.
Topics: Adenosine Triphosphate; Cells, Cultured; Cilia; Cystic Fibrosis; Electrophysiology; Extracellular Fl | 2007 |
High-attenuation mucus plugs on MDCT in a child with cystic fibrosis: potential cause and differential diagnosis.
Topics: Aspergillosis, Allergic Bronchopulmonary; Bronchoscopy; Child; Cystic Fibrosis; Diagnosis, Different | 2007 |
Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine.
Topics: Acetylcysteine; Animals; Bacteria; Body Weight; Cathartics; Cystic Fibrosis; Disease Models, Animal; | 2007 |
Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis.
Topics: Acetylcholine; Animals; Carbachol; Cholinergic Agonists; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosi | 2007 |
Differential epithelial expression of the putative innate immune molecule SPLUNC1 in cystic fibrosis.
Topics: Animals; Cell Culture Techniques; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Cystic Fibrosi | 2007 |
Cystic fibrosis of the pancreas.
Topics: Acetylcysteine; Anti-Bacterial Agents; Bronchi; Bronchial Diseases; Child; Cystic Fibrosis; Digestiv | 1966 |
Mucoid impaction of the bronchi in cystic fibrosis.
Topics: Adolescent; Adult; Bronchial Diseases; Bronchoscopy; Child; Child, Preschool; Cystic Fibrosis; Femal | 1967 |
N-acetylcysteine in cystic fibrosis. Mechanical and chemical factors in treatment by aerosol.
Topics: Acetylcysteine; Adolescent; Adult; Aerosols; Agammaglobulinemia; Bronchiectasis; Child; Child, Presc | 1967 |
The composition of rectal mucus in cystic fibrosis.
Topics: Carbohydrates; Chromatography, Gas; Cystic Fibrosis; Fucose; Humans; Mucus; Neuraminic Acids; Rectum | 1967 |
Studies on pulmonary secretions. II. Osmolality and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy.
Topics: Amino Acids; Bronchiectasis; Calcium; Carbohydrates; Chlorides; Cystic Fibrosis; Humans; Laryngectom | 1967 |
Clinical findings and research in cystic fibrosis.
Topics: Chlorides; Cystic Fibrosis; Exocrine Glands; Lung Diseases; Mucus; Pancreas; Saliva; Sodium; Sweat | 1967 |
Mucous retention and overinflation as basic pulmonary complications in cystic fibrosis (mucoviscidosis).
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Lung; Male; Mucus; Pulm | 1967 |
Oral administration of n-acetyl cysteine in the prophylaxis of "meconium ileus equivalent".
Topics: Acetylcysteine; Adult; Cystic Fibrosis; Enema; Humans; Intestinal Obstruction; Male; Meconium; Mucus | 1967 |
Intussusception in a patient with cystic fibrosis: a case report.
Topics: Cystic Fibrosis; Fecal Impaction; Female; Humans; Ileum; Infant; Intestinal Obstruction; Intussuscep | 1967 |
Pulmonary mucociliary clearance.
Topics: Asthma; Cilia; Cystic Fibrosis; Humans; Kartagener Syndrome; Lung; Mucus; Respiratory Tract Diseases | 1982 |
Cystic fibrosis: a disorder of calcium-stimulated secretion and transepithelial sodium transport?
Topics: Amiloride; Biological Transport, Active; Bronchi; Calcium; Cystic Fibrosis; Epithelium; Humans; Mode | 1982 |
Autonomic nervous system abnormalities in cystic fibrosis.
Topics: Animals; Autonomic Nervous System; Cardiovascular System; Cystic Fibrosis; Dogs; Eccrine Glands; Hum | 1983 |
Pseudomonas aeruginosa mucoid strain: its significance in adult chest diseases.
Topics: Bronchiectasis; Cystic Fibrosis; Humans; Mucus; Pseudomonas aeruginosa | 1983 |
Does chest physical therapy move airway secretions?
Topics: Animals; Bronchial Diseases; Cough; Cystic Fibrosis; Humans; Mucus; Pneumonia; Posture; Respiratory | 1984 |
Scanning electron microscopic study of the airways in normal children and in patients with cystic fibrosis and other lung diseases.
Topics: Adolescent; Adult; Bronchi; Child; Child, Preschool; Cilia; Cystic Fibrosis; Female; Humans; Infant; | 1984 |
Mechanisms of mucous transport.
Topics: Cilia; Cough; Cystic Fibrosis; Humans; Mathematics; Models, Biological; Movement; Mucus; Respiration | 1983 |
Primary ciliary dyskinesia: what has it taught us about pulmonary disease?
Topics: Bronchi; Cilia; Cough; Cystic Fibrosis; Humans; Kartagener Syndrome; Lung Diseases; Movement; Mucus; | 1983 |
The composition of a mucus glycoprotein from meconium of cystic fibrosis, healthy pre-term and full-term neonates.
Topics: Carbohydrates; Cystic Fibrosis; Gestational Age; Glycoproteins; Humans; Infant, Newborn; Infant, Pre | 1983 |
Further evidence for a flexible and highly expanded spheroidal model for mucus glycoproteins in solution.
Topics: Cystic Fibrosis; Female; Glycoproteins; Humans; Microscopy, Electron; Models, Chemical; Molecular We | 1983 |
The chronically isoproterenol-treated rat in the study of cystic fibrosis: X-ray microanalysis of the submandibular gland.
Topics: Animals; Calcium; Cystic Fibrosis; Disease Models, Animal; Drug Interactions; Electron Probe Microan | 1984 |
Complex structure of human bronchial mucus glycoprotein.
Topics: Amino Acids; Bronchi; Bronchitis; Carbohydrates; Chemical Phenomena; Chemistry, Physical; Child; Chr | 1984 |
Primary structure determination of five sialylated oligosaccharides derived from bronchial mucus glycoproteins of patients suffering from cystic fibrosis. The occurrence of the NeuAc alpha(2----3)Gal beta(1----4)[Fuc alpha(1----3)] GlcNAc beta(1----.) str
Topics: Bronchi; Carbohydrate Conformation; Carbohydrate Sequence; Cystic Fibrosis; Glycoproteins; Humans; M | 1984 |
Contrast enemas in cystic fibrosis: implications of appendiceal nonfilling.
Topics: Abdomen; Adolescent; Adult; Appendicitis; Child; Child, Preschool; Contrast Media; Cystic Fibrosis; | 1981 |
Circulating immune complexes in lung disease.
Topics: Adrenal Cortex Hormones; Antigen-Antibody Complex; Cystic Fibrosis; Humans; Lung Diseases; Macrophag | 1981 |
Mucoid Pseudomonas aeruginosa in cystic fibrosis.
Topics: Adolescent; Child; Cystic Fibrosis; Humans; Mucus; Pseudomonas aeruginosa; Respiratory Tract Infecti | 1982 |
Entry of [3H]water and [1,2-14C]polyethylene glycol 4000 into normal and cystic fibrosis salivary mucus.
Topics: Adolescent; Adult; Carbon Radioisotopes; Child; Cystic Fibrosis; Female; Humans; Male; Mucus; Permea | 1983 |
Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis.
Topics: Cough; Cystic Fibrosis; Drainage; Forced Expiratory Volume; Humans; Mucus; Posture | 1983 |
Mucus glycoproteins secreted by respiratory epithelial tissue from cystic fibrosis patients.
Topics: Bronchi; Cystic Fibrosis; Epithelium; Glycoproteins; Humans; Mucus; Nasal Mucosa; Nasal Polyps; Resp | 1983 |
Control and modulation of airway epithelial cells and their secretions.
Topics: Animals; Asthma; Bronchitis; Chronic Disease; Cystic Fibrosis; Disease Models, Animal; Dogs; Epithel | 1983 |
Isolation of fatty acids covalently bound to the gastric mucus glycoprotein of normal and cystic fibrosis patients.
Topics: Centrifugation, Density Gradient; Chromatography, Gel; Cystic Fibrosis; Electrophoresis, Polyacrylam | 1983 |
Polyelectrolyte behaviour in mucus glycoproteins.
Topics: Cystic Fibrosis; Female; Glycoproteins; Guanidine; Guanidines; Humans; Molecular Weight; Mucus; Osmo | 1983 |
Differences in mucus-stimulating serum fractions of cystic fibrosis patients and controls.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Cystic Fibrosis; Female; Heterozygote; Homo | 1983 |
Could a defect in host-immunity be the cause of respiratory infections?
Topics: Adult; Agammaglobulinemia; Aged; Child; Cilia; Cystic Fibrosis; Female; Humans; Lung Diseases, Obstr | 1981 |
Effect of normal and cystic fibrotic serum on ion transport and mucus glycoprotein secretion from the isolated rabbit trachea.
Topics: Animals; Biological Transport; Blood Physiological Phenomena; Chlorides; Cystic Fibrosis; Female; Gl | 1982 |
[Tracheobronchial mucociliary clearance. Physiopathologic significance and clinical importance].
Topics: Bronchi; Cilia; Cystic Fibrosis; Humans; Kartagener Syndrome; Mucus; Respiratory Tract Diseases; Tra | 1981 |
A purified serum glycopeptide from controls and cystic fibrosis patients. I. Comparison of their mucociliary activity on rabbit tracheal explants.
Topics: Adolescent; Adult; Animals; Chemical Phenomena; Chemistry; Child; Child, Preschool; Cilia; Cystic Fi | 1982 |
Differences in mucus glycoproteins of small intestine from subjects with and without cystic fibrosis.
Topics: Amino Acids; Carbohydrate Metabolism; Centrifugation, Density Gradient; Cystic Fibrosis; Glycoprotei | 1982 |
Primary-structure determination of fourteen neutral oligosaccharides derived from bronchial-mucus glycoproteins of patients suffering from cystic fibrosis, employing 500-MHz 1H-NMR spectroscopy.
Topics: Chemical Phenomena; Chemistry; Cystic Fibrosis; Glycoproteins; Humans; Hydrogen-Ion Concentration; M | 1982 |
Bronchial mucous glands in the newborn with cystic fibrosis.
Topics: Bronchi; Cystic Fibrosis; Female; Humans; Infant, Newborn; Intestine, Small; Male; Mucus; Respirator | 1982 |
Reevaluation of the action of reducing agents on soluble mucus glycoproteins from human bronchial secretion.
Topics: Alkylation; Bronchi; Bronchitis; Child; Cystic Fibrosis; Glycoproteins; Humans; In Vitro Techniques; | 1981 |
Stimulation of glycoprotein secretion in dispersed rat submandibular gland acini by cystic fibrosis serum.
Topics: Animals; Cystic Fibrosis; Glycoproteins; Heterozygote; Homozygote; Humans; Mucus; Rats; Respiratory | 1981 |
Is cystic fibrosis mucus abnormal?
Topics: Animals; Anura; Biological Transport; Cystic Fibrosis; Dogs; Elasticity; Mucus; Sputum; Viscosity | 1981 |
Alteration of tracheal mucociliary transport in airway disease. Effect of pharmacologic agents.
Topics: Animals; Asthma; Bronchitis; Bronchodilator Agents; Chromones; Cilia; Cystic Fibrosis; Dogs; Humans; | 1981 |
Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis.
Topics: Adolescent; Adult; Bronchiectasis; Cilia; Cystic Fibrosis; Humans; Mucus; Nasal Mucosa; Sinusitis; T | 1981 |
Cystic fibrosis serum effects on rabbit tracheal epithelium: an ultrastructural analysis.
Topics: Animals; Cilia; Cystic Fibrosis; Epithelium; Heterozygote; Humans; Mucus; Rabbits; Trachea | 1980 |
Mucus-stimulating activity in the sera of patients with cystic fibrosis: demonstration and preliminary fractionation.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chromatography, Agarose; Cystic Fibrosis; Femal | 1980 |
Coupled secretion of chloride and mucus in skin of Xenopus laevis: possible role for CFTR.
Topics: Animals; Chlorides; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator | 1994 |
Symptom outcome after functional endoscopic sinus surgery in patients with cystic fibrosis: a prospective study.
Topics: Activities of Daily Living; Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Endoscopy; | 1995 |
The pathophysiological role of mucus production in inflammatory airway diseases.
Topics: Asthma; Bronchitis; Cystic Fibrosis; Forced Expiratory Volume; Humans; Lung Diseases, Obstructive; M | 1995 |
[Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis].
Topics: Adolescent; Adult; Child; Cough; Cystic Fibrosis; Deoxyribonuclease I; Expectorants; Humans; Mucocil | 1995 |
Localization of the cystic fibrosis transmembrane conductance regulator in airway secretory glands.
Topics: Animals; Blotting, Western; Cattle; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane | 1993 |
Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
Topics: Administration, Inhalation; Adult; Cough; Cystic Fibrosis; Deoxyribonuclease I; Dose-Response Relati | 1995 |
Effect of enhanced supramaximal flows on cough clearance.
Topics: Adult; Aged; Computers; Cough; Cystic Fibrosis; Female; Humans; Lung; Lung Diseases, Obstructive; Ma | 1994 |
Magnetic resonance scanning in cystic fibrosis: comparison with computed tomography.
Topics: Adolescent; Adult; Bronchi; Bronchiectasis; Bronchography; Child; Cystic Fibrosis; Dilatation, Patho | 1995 |
Viscosity versus composition in airway pathology.
Topics: Cystic Fibrosis; Humans; Mucus; Respiratory System; Viscosity | 1994 |
Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus.
Topics: Animals; Cough; Cystic Fibrosis; Drug Carriers; Humans; In Vitro Techniques; Liposomes; Mucociliary | 1993 |
Direct double antibody sandwich immunoassay of mucin M1 epitopes in human mucus secreting pancreatic cell lines.
Topics: Antibodies, Monoclonal; Antibody Specificity; Bacterial Proteins; Biotin; Cell Line; Cystic Fibrosis | 1995 |
Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Bronchi; Cystic Fibrosis; Diffusion; Glycoprote | 1996 |
Mucoid impaction presenting as multiple pulmonary nodules in cystic fibrosis.
Topics: Adult; Bronchial Diseases; Cystic Fibrosis; Diagnosis, Differential; Humans; Lung Neoplasms; Male; M | 1996 |
Differential gene expression by Pseudomonas aeruginosa during interaction with respiratory mucus.
Topics: Animals; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Humans; Mice; Mucins; Mucus; Pseudo | 1996 |
Isolation and characterization of Pseudomonas aeruginosa genes inducible by respiratory mucus derived from cystic fibrosis patients.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; Chromosome Mapping; Cystic Fibrosis; DNA, Ba | 1996 |
Chronic rhinosinusitis in cystic fibrosis (mucoviscidosis).
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Chron | 1997 |
Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus.
Topics: Acetylcholine; Animals; Bicarbonates; Bronchi; Chemical Phenomena; Chemistry, Physical; Chlorides; C | 1998 |
Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
Topics: Adolescent; Adult; Analysis of Variance; Animals; Anura; Bacterial Adhesion; Chemical Phenomena; Che | 1998 |
Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile.
Topics: Adult; Cystic Fibrosis; Deoxyribonucleases; Elasticity; Female; Humans; Lipids; Male; Mucociliary Cl | 1998 |
The intrapulmonary percussive ventilator and flutter device compared to standard chest physiotherapy in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Cystic Fibrosis; Female; Humans; Lung; Male; Mucus; Physical Therapy Modal | 1998 |
USAN Council. List No.405. New names. Dornase alfa.
Topics: Amino Acid Sequence; Cystic Fibrosis; Deoxyribonuclease I; Expectorants; Humans; Molecular Sequence | 1998 |
Molecular pathophysiology of cystic fibrosis based on the rescued knockout mouse model.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Anima | 1998 |
Mucus transportability: the bovine trachea and frog palate models compared.
Topics: Animals; Anura; Cattle; Cystic Fibrosis; Disease Models, Animal; Humans; Mucociliary Clearance; Mucu | 1998 |
Cystic fibrosis mice lacking Muc1 have reduced amounts of intestinal mucus.
Topics: Animals; Cystic Fibrosis; Digestive System; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Kn | 1998 |
Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.
Topics: Absorption; Animals; Bacterial Infections; Body Water; Bronchi; Cell Culture Techniques; Cells, Cult | 1998 |
The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium.
Topics: Adenoviridae; Animals; beta-Galactosidase; Cell Membrane; COS Cells; Cystic Fibrosis; Epithelium; Fl | 1999 |
Manipulation of volume vs osmolality in cystic fibrosis lung disease.
Topics: Absorption; Adult; Child; Cystic Fibrosis; Defensins; Humans; Lung; Mucus; Neutrophils; Osmolar Conc | 1999 |
Almost serendipity: alcoholism drug reverses drug resistance in vitro.
Topics: Alcohol Deterrents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capsaicin; Cystic Fibro | 2000 |
Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms.
Topics: 4-Butyrolactone; Biofilms; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Lung; Mucus; Pseu | 2000 |
Application of chest high-resolution computer tomography in young children with cystic fibrosis.
Topics: Age Factors; Bronchiectasis; Bronchography; Child; Child, Preschool; Cystic Fibrosis; Female; Forced | 2001 |
Thick mucus hypothesis in cystic fibrosis.
Topics: Cystic Fibrosis; Humans; Mucociliary Clearance; Mucus; Pseudomonas Infections | 2001 |
Exercise inhibits epithelial sodium channels in patients with cystic fibrosis.
Topics: Adolescent; Adult; Amiloride; Child; Cystic Fibrosis; Diuretics; Epithelium; Exercise; Exercise Test | 2001 |
The CF salt controversy: in vivo observations and therapeutic approaches.
Topics: Aerosols; Amiloride; Animals; Cells, Cultured; Cystic Fibrosis; Disease Models, Animal; Diuretics; G | 2001 |
Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B.
Topics: Asthma; Blotting, Western; Cystic Fibrosis; Dose-Response Relationship, Drug; Electrophoresis, Agar | 2002 |
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
Topics: Adult; Aerobiosis; Anaerobiosis; Cystic Fibrosis; Female; Humans; Hypoxia; Male; Microscopy, Electro | 2002 |
Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus.
Topics: Albumins; Cystic Fibrosis; DNA; Fatty Acids, Monounsaturated; Gene Expression; Genetic Therapy; Huma | 2002 |
CT characterization of inflammatory paranasal sinus disease in cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Male; Mucus; Paranasal | 2002 |
In vivo microdialysis for determination of nasal liquid ion composition.
Topics: Animals; Chlorides; Cystic Fibrosis; Disease Models, Animal; Electrodes; Female; Ions; Male; Membran | 2002 |
Fatty-acid composition of lecithin fraction of mucus in cystic fibrosis.
Topics: Bronchi; Child; Cystic Fibrosis; Fatty Acids, Essential; Humans; Mucus; Phosphatidylcholines | 1977 |
Lectins and cystic fibrosis.
Topics: Animals; Concanavalin A; Cystic Fibrosis; Exocrine Glands; Humans; Mucus; Rats | 1978 |
Mucopolysaccharides in bronchial secretion of children.
Topics: Asthma; Bronchi; Bronchitis; Child; Cystic Fibrosis; Glycosaminoglycans; Humans; Infant; Mucus | 1978 |
The influence of cystic fibrosis serum and calcium on secretion in the rabbit tracheal mucociliary apparatus.
Topics: Animals; Calcimycin; Calcium; Culture Techniques; Cystic Fibrosis; Epithelium; Heterozygote; Immunog | 1978 |
Differential pathology of nasal polyps in cystic fibrosis and atopy.
Topics: Adolescent; Adult; Basement Membrane; Child; Child, Preschool; Cystic Fibrosis; Exocrine Glands; Fem | 1979 |
Development of an improved tracheal explant bioassay for the detection of the ciliary dyskinesia factor in cystic fibrosis serum.
Topics: Animals; Cilia; Cricetinae; Culture Media; Cystic Fibrosis; Cytotoxins; Female; Guinea Pigs; Humans; | 1979 |
[Tracheobronchial endoscopy in children].
Topics: Age Factors; Anesthesia; Asthma; Bronchi; Bronchial Diseases; Bronchial Fistula; Bronchial Neoplasms | 1979 |
Pathogenesis of cystic fibrosis: possible importance of alteration in epithelial surface topography.
Topics: Cell Membrane; Cystic Fibrosis; Epithelium; Humans; Lung; Microscopy, Electron, Scanning; Mucous Mem | 1979 |
Cystic fibrosis: potential management through manipulation of the secretory process in affected exocrine glands.
Topics: Animals; Cats; Cystic Fibrosis; Exocrine Glands; Ferrets; Isoproterenol; Macromolecular Substances; | 1979 |
Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases.
Topics: Asthma; Bronchial Diseases; Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Female; Fu | 1978 |
Rectal mucosa in cystic fibrosis. Morphological features before and after short term organ culture.
Topics: Adolescent; Adult; Autoradiography; Biopsy; Child; Cystic Fibrosis; Epithelium; Humans; Intestinal M | 1978 |
Neonatal meconium obstruction in the ileum without mucoviscidosis.
Topics: Contrast Media; Cystic Fibrosis; Enema; Female; Humans; Hypertonic Solutions; Hypertrophy; Ileum; In | 1978 |
The biochemical basis of cystic fibrosis: an hypothesis based upon the polyelectrolytes of mucus.
Topics: Cystic Fibrosis; Electrolytes; Humans; Membrane Proteins; Membranes; Mucus; Viscosity | 1978 |
Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production.
Topics: Acetylcysteine; Cetrimonium Compounds; Citrates; Culture Media; Cystic Fibrosis; Deoxycholic Acid; F | 1975 |
Cystic fibrosis--related inhibition of mucociliary clearance in vivo in man.
Topics: Adolescent; Adult; Child; Cilia; Cystic Fibrosis; Humans; Immunoglobulin E; Mucus; Nasal Mucosa | 1977 |
Effects of gravity on tracheal mucus transport rates in normal subjects and in patients with cystic fibrosis.
Topics: Adolescent; Adult; Cystic Fibrosis; Female; Gravitation; Humans; Male; Mucus; Posture; Radionuclide | 1977 |
Treatment of mucus hypersecretion in human disease.
Topics: Airway Obstruction; Atropine; Bronchial Diseases; Cystic Fibrosis; Exudates and Transudates; Glycopr | 1977 |
Composition of nasal secretion in patients with cystic fibrosis.
Topics: Adolescent; Adult; Albumins; Child; Cystic Fibrosis; Humans; Immunoglobulin A; Immunoglobulin G; Muc | 1976 |
Human respiratory tract secretion. Mucous glycoproteins of nonpurulent tracheobronchial secretions, and sputum of patients with bronchitis and cystic fibrosis.
Topics: Adolescent; Amino Acids; Bronchitis; Cystic Fibrosis; Female; Fucose; Galactose; Glycoproteins; Hexo | 1976 |
Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).
Topics: Acetylcysteine; Aerosols; Arginine; Bronchoscopy; Carbon Dioxide; Child; Child, Preschool; Cough; Cy | 1975 |
Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis.
Topics: Age Factors; Autopsy; Bile Ducts, Intrahepatic; Cholestasis; Cystic Fibrosis; Humans; Infant; Infant | 1975 |
Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline.
Topics: Adolescent; Adult; Airway Obstruction; Bronchoscopy; Cilia; Cystic Fibrosis; Female; Humans; Male; M | 1975 |
Comparative pathology of marine invertebrates and the study of human disease.
Topics: Animals; Arachnida; Bivalvia; Brachyura; Cystic Fibrosis; Humans; Marine Biology; Models, Biological | 1975 |
An animal model for cystic fibrosis made by gene targeting.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Digestive System; Dis | 1992 |
Influence of nutrient media on the chemical composition of the exopolysaccharide from mucoid and non-mucoid Pseudomonas aeruginosa.
Topics: Alginates; Bronchiectasis; Culture Media; Cystic Fibrosis; Glucuronic Acid; Hexuronic Acids; Humans; | 1992 |
Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.
Topics: Adolescent; Adult; Alginates; Antibodies, Bacterial; Child; Child, Preschool; Cystic Fibrosis; Enzym | 1992 |
Pseudomonas aeruginosa is retained in the bronchi of cystic fibrotics by the increased transepithelial potential.
Topics: Bronchi; Cystic Fibrosis; Electrophysiology; Epithelium; Humans; Models, Biological; Mucus; Pseudomo | 1992 |
Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchiectasis; Child; Cystic Fibrosis; Humans; Lung Dis | 1992 |
A superficial view of mucus and the cystic fibrosis defect.
Topics: Cystic Fibrosis; Humans; Mucus; Sputum | 1992 |
Work of adhesion of respiratory tract mucus.
Topics: Adolescent; Animals; Child; Cystic Fibrosis; Dogs; Humans; Mucus; Osmolar Concentration; Respiratory | 1992 |
The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases.
Topics: Amikacin; Anti-Bacterial Agents; Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Human | 1992 |
Mucus clearance with three chest physiotherapy regimes in cystic fibrosis: a comparison between postural drainage, PEP and physical exercise.
Topics: Adult; Breathing Exercises; Cystic Fibrosis; Drainage, Postural; Exercise Therapy; Female; Humans; L | 1992 |
Detection of distinct species in purified human respiratory mucin using monoclonal antibodies.
Topics: Antibodies, Monoclonal; Blotting, Western; Bronchi; Chromatography, Affinity; Cystic Fibrosis; Human | 1991 |
Chronic bronchial secretion in delta F508 heterozygote for cystic fibrosis.
Topics: Blood Proteins; Bronchi; Calgranulin A; Chronic Disease; Cystic Fibrosis; Genetic Carrier Screening; | 1991 |
Production and characterization of monoclonal antibodies to purified deglycosylated cystic fibrosis respiratory mucin: evidence for the presence of four immunologically distinct epitopes.
Topics: Amino Acids; Animals; Antibodies, Monoclonal; Bronchi; Cystic Fibrosis; Epitopes; Female; Glycosylat | 1991 |
Ultrafast computerized tomography of the chest in cystic fibrosis: a new scoring system.
Topics: Adolescent; Adult; Bronchiectasis; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Mucus; | 1991 |
[Pulmonary complications in cystic fibrosis].
Topics: Adolescent; Adult; Bronchial Diseases; Child; Cystic Fibrosis; Hemoptysis; Humans; Lung Diseases; Mu | 1991 |
Effect of positive expiratory pressure breathing in patients with cystic fibrosis.
Topics: Adolescent; Adult; Cough; Cystic Fibrosis; Forced Expiratory Volume; Functional Residual Capacity; H | 1991 |
The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum.
Topics: Adolescent; Adult; Child; Cystic Fibrosis; DNA; DNA, Bacterial; Female; Glycoproteins; Humans; Male; | 1990 |
Abnormal fucosylation of ileal mucus in cystic fibrosis: I. A histochemical study using peroxidase labelled lectins.
Topics: Cystic Fibrosis; Fucose; Gestational Age; Humans; Ileum; Immunoenzyme Techniques; Infant; Infant, Ne | 1990 |
Abnormal fucosylation of-ileal mucus in cystic fibrosis: II. A histochemical study using monoclonal antibodies to fucosyl oligosaccharides.
Topics: Antibodies, Monoclonal; Cystic Fibrosis; Fucose; Gestational Age; Humans; Ileum; Infant; Infant, New | 1990 |
Water secretion and embryological layers in cystic fibrosis.
Topics: Body Water; Cervix Mucus; Cystic Fibrosis; Ectoderm; Endoderm; Epithelium; Female; Germ Layers; Huma | 1990 |
Effect of covalently bound fatty acids and associated lipids on the viscosity of gastric mucus glycoprotein in cystic fibrosis.
Topics: Adolescent; Adult; Carbohydrates; Child; Child, Preschool; Cystic Fibrosis; Fatty Acids; Female; Gas | 1986 |
Pathophysiology of cystic fibrosis with emphasis on salivary gland involvement.
Topics: Animals; Chlorides; Cystic Fibrosis; Exocrine Glands; Humans; Ion Channels; Mucus; Saliva; Salivary | 1987 |
Evidence for the in vivo degradation of human respiratory mucins during Pseudomonas aeruginosa infection.
Topics: Amino Acids; Blotting, Western; Carbohydrates; Chromatography, Liquid; Cystic Fibrosis; Electrophore | 1989 |
Physical properties of purified human respiratory mucus glycoproteins: effects of sodium chloride concentration on the aggregation properties and shape.
Topics: Adolescent; Adult; Amino Acids; Carbohydrates; Child; Cystic Fibrosis; Female; Guanidine; Guanidines | 1989 |
Physiologic implications of the autonomic aberrations in cystic fibrosis.
Topics: Adult; Airway Obstruction; Airway Resistance; Asthma; Autonomic Nervous System; Bronchi; Bronchial P | 1986 |
The pathogenesis of cystic fibrosis: a proposal for calmodulin as the basic biochemical defect.
Topics: Biological Transport; Calcium; Calmodulin; Cystic Fibrosis; Epithelium; Humans; Mucus; Sodium; Sodiu | 1986 |
Structure determination of five sulfated oligosaccharides derived from tracheobronchial mucus glycoproteins.
Topics: Adolescent; Bronchi; Carbohydrate Conformation; Carbohydrates; Chromatography; Cystic Fibrosis; Glyc | 1987 |
Immunologic aspects of surface infections in the lung.
Topics: Bacterial Vaccines; Cystic Fibrosis; Humans; Immunoglobulins; Lung; Lung Diseases; Macrophages; Muco | 1986 |
Antibody to multiple mucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis, measured by an enzyme-linked immunosorbent assay.
Topics: Adult; Antibodies, Bacterial; Cystic Fibrosis; Double-Blind Method; Enzyme-Linked Immunosorbent Assa | 1986 |
Changes in glycoconjugates in rat submandibular gland after chronic treatment with reserpine and isoproterenol.
Topics: Animals; Cystic Fibrosis; Cytoplasmic Granules; Disease Models, Animal; Glycoconjugates; Isoproteren | 1988 |
Tear mucus crystallization in children with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Crystallization; Cystic Fibrosis; Electrolytes; Humans; | 1988 |
Conventional physiotherapy and forced expiration manoeuvres have similar effects on tracheobronchial clearance.
Topics: Adolescent; Adult; Aerosols; Agammaglobulinemia; Bronchi; Cystic Fibrosis; Humans; Mucus; Respirator | 1988 |
Bronchial clearance in cystic fibrosis.
Topics: Biological Transport; Bronchi; Cilia; Cystic Fibrosis; Humans; Metabolic Clearance Rate; Mucus | 1986 |
Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses.
Topics: Adolescent; Adult; Amiloride; Bronchi; Child; Cilia; Cough; Cystic Fibrosis; Female; Humans; Male; M | 1986 |
Cystic fibrosis, Crohn's colitis, and adult meconium ileus equivalent.
Topics: Adult; Colectomy; Colitis; Crohn Disease; Cystic Fibrosis; Gastrointestinal Hemorrhage; Humans; Inte | 1986 |
Lung defense against infection.
Topics: Antibodies, Bacterial; Bacterial Infections; Complement System Proteins; Cystic Fibrosis; Granulocyt | 1986 |
[Respiratory mucus].
Topics: Animals; Bronchi; Bronchitis; Cystic Fibrosis; Humans; Mucus; Sputum; Viscosity | 1985 |
Rheological and transport properties of airway secretions in cystic fibrosis--relationships with the degree of infection and severity of the disease.
Topics: Adolescent; Biological Transport, Active; Child; Cilia; Cystic Fibrosis; Female; Humans; Male; Mucus | 1985 |
The effects of proteins secreted by fibroblasts from patients with cystic fibrosis on hamster tracheal explants.
Topics: Adolescent; Adult; Animals; Blood Physiological Phenomena; Blood Proteins; Cell Survival; Child; Chi | 1985 |
[Are there mucoviscidosis-specific humoral factors? 2: Function, detection procedures, conclusions].
Topics: Blood Proteins; Calgranulin A; Chemotaxis, Leukocyte; Cilia; Cystic Fibrosis; Humans; Mucous Membran | 1985 |
Mucus glycoprotein fatty acyltransferase in patients with cystic fibrosis: effect on the glycoprotein viscosity.
Topics: Acetyl-CoA C-Acyltransferase; Acyltransferases; Adolescent; Adult; Aged; Biopsy; Child; Child, Presc | 1985 |
Invertebrate model for study of macromolecular regulators of mucus secretion.
Topics: Adult; Amylases; Animals; Annelida; Blood Chemical Analysis; Cells, Cultured; Child; Cystic Fibrosis | 1974 |
Cystic fibrosis o the pancreas. A generalised disturbance of water and electrolyte movement in exocrine tissues.
Topics: Animals; Biological Transport; Biological Transport, Active; Cats; Cell Membrane; Connective Tissue; | 1968 |
Cystic fibrosis of the pancreas. A generalised disturbance of water and electrolyte movement in exocrine tissues.
Topics: Animals; Biological Transport; Biological Transport, Active; Cats; Cell Membrane; Connective Tissue; | 1968 |
On the use of eosin as a fluorescent dye to demonstrate mucous cells and other structures in tissue sections.
Topics: Animals; Colitis, Ulcerative; Cystic Fibrosis; Dogs; Duodenum; Exocrine Glands; Fluoresceins; Gastri | 1969 |
Hyperpermeable mucus in cystic fibrosis.
Topics: Animals; Biological Transport, Active; Calcium; Cell Membrane Permeability; Cystic Fibrosis; Dialysi | 1970 |
Sputum viscosity in cystic fibrosis.
Topics: Bronchiectasis; Bronchitis; Cystic Fibrosis; Diagnosis, Differential; Humans; Mucus; Sputum; Viscosi | 1970 |
The challenge of research on mucus.
Topics: Animals; Biophysical Phenomena; Biophysics; Cystic Fibrosis; Glycosaminoglycans; Humans; Interprofes | 1966 |
[Histochemistry of the mucus in mucoviscidosis].
Topics: Bronchi; Child, Preschool; Cystic Fibrosis; Glycosaminoglycans; Histocytochemistry; Humans; Infant; | 1972 |
Use of ultrasonic aerosols with ventilatory assistors.
Topics: Aerosols; Amphotericin B; Asthma; Bronchial Diseases; Bronchodilator Agents; Cystic Fibrosis; Eosino | 1968 |
An in vitro system for studying mucus secretion and other physiological activities in human intestinal mucosa.
Topics: Amphotericin B; Ampicillin; Autoradiography; Chloramphenicol; Culture Techniques; Cystic Fibrosis; G | 1970 |
Structure and ultrastructure of the labial salivary glands in patients with cystic fibrosis.
Topics: Adolescent; Biopsy; Cell Nucleus; Child; Child, Preschool; Cystic Fibrosis; Female; Histocytochemist | 1971 |
The effects of an inhibitor of Na plus -K plus -active transport on the secretory activity of rat submaxillary gland cell cultures.
Topics: Animals; Animals, Newborn; Biological Transport, Active; Cell Line; Culture Techniques; Cystic Fibro | 1971 |
The water-soluble components of bronchial mucus from patients with cystic fibrosis.
Topics: Albumins; Bronchi; Cystic Fibrosis; Humans; Immunoglobulins; Mucus; Muramidase; Sputum | 1972 |
Mucoid enteritis of rabbits. Comparison to cholera and cystic fibrosis.
Topics: Animals; Blood Glucose; Blood Proteins; Cecum; Cholera; Colon; Cystic Fibrosis; Enteritis; Female; H | 1972 |
Pulmonary mucociliary clearance in cystic fibrosis.
Topics: Adolescent; Adult; Aerosols; Albumins; Child; Cilia; Cystic Fibrosis; Humans; Lung; Mucus; Radionucl | 1973 |
Cilia and cystic fibrosis.
Topics: Aerosols; Albumins; Child; Cilia; Cystic Fibrosis; Humans; Mucus; Technetium; Viscosity | 1973 |
Mucociliary transport in cystic fibrosis.
Topics: Aerosols; Cilia; Cystic Fibrosis; Humans; Mucus; Pulmonary Ventilation; Radionuclide Imaging; Respir | 1973 |
The effect of isoprenaline and pilocarpine on (a) bronchial mucus-secreting tissue and (b) pancreas, salivary glands, heart, thymus, liver and spleen.
Topics: Animals; Bronchi; Cystic Fibrosis; Glycoproteins; Heart; Isoproterenol; Liver; Mucous Membrane; Mucu | 1973 |
[Determination of the immunoglobulin fractions of the blood and bronchial secretions in mucoviscidosis].
Topics: Bronchi; Bronchopneumonia; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Immunoglobulin | 1973 |
[Secretory IgA in the immunologic defence of the bronchial mucosa].
Topics: Bronchi; Bronchial Diseases; Bronchial Neoplasms; Bronchitis; Child; Child, Preschool; Cystic Fibros | 1973 |
The electron microscopic appearance of presecreted gastric mucus in cystic fibrosis.
Topics: Analysis of Variance; Biopsy; Child; Cystic Fibrosis; Gastric Mucosa; Humans; Microscopy, Electron; | 1974 |
Output characteristics and clinical efficacy of ultrasonic nebulizers.
Topics: Acetylcysteine; Aerosols; Asthma; Bronchial Diseases; Child; Cortisone; Cystic Fibrosis; Humans; Muc | 1968 |
[Glycopeptides of bronchial fibrillar mucus in cystic fibrosis].
Topics: Acridines; Animals; Bradykinin; Bronchi; Bronchial Spasm; Child; Chromatography, Ion Exchange; Cysti | 1972 |
Mucus, calcium, sweat, water, and permeability in cystic fibrosis.
Topics: Animals; Calcium; Cell Membrane Permeability; Cystic Fibrosis; Humans; Mucus; Rats; Sweat; Water-Ele | 1972 |
[Isolation of bronchial mucins secreted in cystic fibrosis].
Topics: Animals; Bronchi; Child; Chromatography, Gel; Chromatography, Ion Exchange; Cystic Fibrosis; Electro | 1972 |
Allergy in patients with cystic fibrosis.
Topics: Adolescent; Allergens; Antigens; Child; Child, Preschool; Cystic Fibrosis; Dust; Eosinophils; Hair; | 1972 |
[Electrolytes and proteins of nasal secretion in mucoviscidosis].
Topics: Adolescent; Adult; Body Fluids; Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Humans; Mucu | 1971 |
Cystic fibrosis--a problem of permeability?
Topics: Animals; Calcium; Cell Membrane Permeability; Cystic Fibrosis; Exocrine Glands; Mucus; Permeability; | 1971 |
[Mucolytic agents for inhalation].
Topics: Acetylcysteine; Aerosols; Cystic Fibrosis; Humans; Mucus; Respiratory Therapy | 1970 |
Cystic fibrosis.
Topics: Abdomen, Acute; Aerosols; Anti-Bacterial Agents; Breathing Exercises; Cough; Cystic Fibrosis; Draina | 1970 |
The intestinal radiological changes in older people with pancreatic cystic fibrosis.
Topics: Adult; Biopsy; Colon; Cystic Fibrosis; Duodenum; Humans; Ileum; Intestines; Male; Mucus; Radiography | 1971 |
[Biochemical studies of bronchial secretions in mucoviscidosis of children].
Topics: Amino Acids; Child; Child, Preschool; Chromatography, Gel; Chromatography, Ion Exchange; Cystic Fibr | 1971 |
Parotid secretions in cystic fibrosis. Effect on zeta potential of tracheal mucus.
Topics: Adsorption; Amylases; Animals; Calcium Chloride; Cystic Fibrosis; Depression, Chemical; Dogs; Electr | 1971 |
The histochemical type of glycoprotein produced by mucous cells of normal and diseased bronchi in childhood.
Topics: Bronchi; Bronchiectasis; Child; Child, Preschool; Cystic Fibrosis; Glycoproteins; Humans; Mucins; Mu | 1971 |
Sodium-potassium measurement interferences in various biological fluids.
Topics: Body Fluids; Cystic Fibrosis; Intestinal Secretions; Methods; Mucus; Photometry; Potassium; Saliva; | 1968 |
Pulmonary changes and cor pulmonale in mucoviscidosis.
Topics: Adult; Bronchiectasis; Bronchopneumonia; Child; Child, Preschool; Cystic Fibrosis; Female; Granulati | 1968 |
Disturbances in the pattern of secretion of bronchial mucous glands.
Topics: Animals; Atropine; Bronchi; Cystic Fibrosis; Glycoproteins; Humans; Mucous Membrane; Mucus; Parasymp | 1968 |
Pulmonary mucus in cystic fibrosis: interrelationships with pathogenic bacteria.
Topics: Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Male; Mucus; Staphylococcus | 1965 |
Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; DNA; Humans; In Vitro Techniques; Lung; Mucus; RNA | 1965 |
Simple method for measuring the penetration of antibiotics through mucus.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Mucus | 1966 |
Mucolytic agent.
Topics: Acetylcysteine; Bronchitis; Cystic Fibrosis; Humans; Mucus; Tracheotomy | 1966 |